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Abstract 
The primary aim of the research I have undertaken is to better understand the 
influence of dopamine on behavior and to build on knowledge of the various roles 
of dopamine in the healthy brain but also to improve understanding of the deficits 
affecting patients with Parkinson’s disease (PD), the hallmark of which is dopamine 
depletion.  
By testing PD patients on cognitive and motor tasks, we are able to probe the 
effects of dopamine depletion in humans. Testing PD patients in different 
medication states also provides a method with which to attempt to tease apart the 
various roles of dopamine from each other. My first two experiments use the PD 
model to this end whereas the third experiment utilises a pharmacological 
manipulation in healthy individuals. 
The aim of my first experiment was to tease apart the relative contribution of 
dopamine to learning from its influence on action performance, and by doing this to 
better understand the deficits which have been observed in PD patients in 
reinforcement learning tasks.  
The second experiment focuses on the motor deficits observed in PD. The aim of 
this study was to test whether these motor deficits can at least in part explained by 
the deficits in reward sensitivity. 
The third and final experiment in this thesis uses a pharmacological manipulation in 
healthy individuals to isolate the role of dopamine in set shifting in the context of a 
response to cues with negative hedonic valence, with the hope of better 
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understanding the neurobiology underlying pathological behaviours associated with 
the hyperdopaminergic state.  
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1.1 Outline of thesis 
Dopamine is a central neurotransmitter in the basal ganglia and influences many 
different aspects of behaviour. The primary aims of the research I have undertaken 
are to: (i) build on the knowledge of role of dopamine in the healthy brain and 
specifically its influence on cognition; (ii) improve our understanding of the 
cognitive deficits affecting patients with Parkinson’s disease (PD).  
As PD is characterised by dopaminergic cell loss, it provides a valuable human 
model of the dopamine depleted state.  By observing deficits present in PD patients 
and the effect of dopaminergic medication on these deficits, it is possible to make 
inferences about the function of dopamine in the healthy brain while also learning 
about the manifestations of a hypodopaminergic state in this patient population.  
PD is a common, progressive degenerative neurological disorder (Pavese & Brooks 
2009) with prevalence rates standing at 1.8% in people over the age of 65 (de Rijk 
et al 2000). The central feature of PD is loss of dopaminergic pigmented neurons in 
the substantia nigra pars compacta (SNc) leading, among other effects, to 
decreased levels of dopamine in the striatum (Koller & Melamed 2007b). By testing 
PD patients on cognitive and motor tasks, I was able to probe the effects of 
dopamine depletion in humans. Testing PD patients ON and OFF dopamine 
replacement therapy (DRT) provides a method with which to attempt to tease apart 
the various roles of dopamine from one another, and ultimately to answer key 
questions surrounding  how dopamine modulation exerts its effects on aspects of 
cognition,  movement, and the interplay between the two.  
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The first two experiments in this thesis use the PD model to this end while the third 
experiment utilises a pharmacological manipulation in healthy individuals.  
The aim of my first experiment was to distinguish the influence of dopamine on 
learning from its influence on action performance and thus better understand the 
relative contribution of dopamine to learning and performance.  In doing so, we 
hoped to explain the deficits which have been observed in PD patients, as seen for 
example in reinforcement learning tasks.  
The second experiment examines the motor deficits observed in PD. The aim of this 
study was to test whether the motor deficits found in PD patients can, at least  in 
part, be explained by insensitivity to reward observed in this group, suggesting that 
there may be a carryover from the cognitive to the motor domain in PD. 
 
In order to probe the effect of dopaminergic modulation further, the third and final 
experiment in this thesis uses a pharmacological manipulation in healthy individuals 
to isolate the role of dopamine in set shifting in the context of a response to cues 
with negative hedonic valence, with the hope of better understanding the 
neurobiology underlying pathological behaviours associated with the 
hyperdopaminergic state.  
 
It is impossible to investigate the role of dopamine without understanding the basic 
neuroanatomy and physiology of the basal ganglia.  I begin this thesis by 
considering this neuroanatomical background and giving an overview of the 
biochemistry of dopamine synthesis. I then discuss the seminal research in the area 
and conclude this section with a discussion on PD.        
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1.2 Neuroanatomy of the basal ganglia and dopamine 
system 
1.2.1 Overview 
The basal ganglia are a group of subcortical nuclei which have long been linked to 
movement control. As such, diseases affecting the basal ganglia (such as PD) are 
primarily associated with movement disorders (Koller & Melamed 2007b), although 
it is now clear that these diseases are also associated with cognitive deficits (Lees & 
Smith 1983). The basal ganglia are often divided into the dorsal division which 
consists of the neostriatum (caudate nucleus and putamen),  the external and 
internal segments of the globus pallidus (GPe and GPi), the subthalamic nucleus 
(STN), and the substantia nigra pars reticulate (SNr)  and pars compacta (SNc) and a 
ventral division consisting of nucleus accumbens (NAc), the ventral pallidum (VP) 
and ventral tegmental area (VTA) (Koller & Melamed 2007b).  
Each basal ganglia nucleus is histologically distinct. The most abundant striatal cell 
type is the GABAergic medium spiny projection neuron, which represent 90–95% of 
all striatal neurons. These cells receive inputs from the cortex and thalamus and 
also intrinsic connections from inhibitory striatal interneurons, including cholinergic 
neurons. In addition they receive modulatory inputs from the dopaminergic and 
sertoninergic cells originating in the midbrain. The dopaminergic projection fibres 
terminate on the neck of the dendritic spines of striatal medium spiny neurons and 
are thus in a position to modulate corticostriatal information flow. As opposed to 
the heterogenous histological organisation of the striatum, The GPe and GPi are 
more homogeneous and contain only very few interneurons. The STN is distinct 
from the other basal ganglia nuclei due to its densely packed structure whose 
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neurons are excitatory and glutamatergic (Koller & Melamed 2007b). As well as 
dopamine cells (Swanson 1982) all divisions of the midbrain also contain substantial 
amounts of GABAergic cells (Nair-Roberts et al 2008).  The VTA receives excitatory 
inputs from widely distributed brain areas indicating  that rather than the VTA being 
influenced by a discrete set of brain structures it is likely to be regulated by an 
integrated network of inputs (Geisler & Zahm 2005). The only cortical structure 
however with a major projection to the VTA originates from the PFC (Sesack & 
Grace 2010) however the exact function of this pathway remains unclear although 
it appears to play a role in plasticity of dopamine neurons (Wolf et al 2004). It has 
also been demonstrated that PFC axons synapse onto dopamine neurons that then 
project back to the PFC creating a circuit which allows the PFC to regulate the 
extent of its modulatory feedback by dopamine (Carr & Sesack 2000). There is also 
major inhibitory feedback from the basal ganglia to the VTA and SNc (Sesack & 
Grace 2010). Recently a major ascending source of inhibition from the mesopontine 
rostromedial tegmental nucleus to the SNc has been discovered. This structure, 
which consists primarily of GABA cells, receives afferents from many forebrain and 
brainstem structures and has widespread projections to the SNc and VTA and is 
therefore in a critical position to inhibit dopamine cell firing in response to aversive 
stimuli (Jhou et al 2009). In addition, serotonin neurons in the dorsal raphe nucleus 
synapse onto dopaminergic cells (Van Bockstaele et al 1994). In summary, the VTA 
receives influences from multiple ascending, descending and intrinsic sources 
however the functional significance of each afferent in relation to reward has yet to 
be fully determined (Sesack & Grace 2010).   
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1.2.2  Loops of the basal ganglia – extrinsic connections 
The basal ganglia receive glutametergic inputs from the cortex and the thalamus 
and have numerous intrinsic connections. The main input structure of the basal 
ganglia is the striatum and the main output structures are the GPi and SNr (Koller & 
Melamed 2007b). The relaying of information through the basal ganglia is 
implemented through spatially segregated but partially overlapping  ‘loops’ from 
the cortex to the basal ganglia, through to the thalamus and back to the cortex 
(Alexander et al 1986). The overlapping of connections from cortical sites to 
different basal ganglia subregions is thought to allow for both parallel and 
integrative networks (Draganski et al 2008; Haber 2003), as well as for the 
channeling of information across these functional circuits (Haber 2003). Information 
is also channelled between the separate basal ganglia loops at the relays of the 
basal ganglia and the thalamus (McFarland & Haber 
 2002; Redgrave et al 2010).  
There is a strong topographical organisation of the projections from the cortex to 
the striatum. In primates, the motor and somatosensory cortices project to the 
postcommissural putamen, the associative cortices to the caudate nucleus and the 
precommissural putamen. The limbic cortices, the amygdala and the hippocampus 
terminate preferentially in the ventral striatum (see figure I.I for schematic 
depiction).  
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Limbic MotorSensoryAssociative
Cerebral   Cortex
Striatum
Pallidum/substantia nigra
Thalamus
 
 
Figure I.I: Represented in this figure are parallel projecting basal ganglia loops 
which convey information from the cortex via the basal ganglia and thalamus 
conveying limbic (red/yellow), associative (yellow/green) and sensorimotor 
(green/blue) information. The topography of the territories are maintained 
throughout the basal ganglia and thalamic relays, albeit with overlap of connections 
from the cortex. There is an opportunity for modulation of activity inside these loops 
specifically at relays in the thalamus and basal ganglia and also by virtue of partially 
overlapping cortical connections. The purple arrows indicate glutametergic 
projections while pink arrows represent GABA-ergic projections. (Figure reproduced 
from Redgrave et al (Redgrave et al 2010)). 
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As well as the corticostriatal projections there are also thalamostriatal projections 
which provide a major source of excitatory afferents. In addition there is a fast 
(single-synaptic) connection between the cortex and thalamus through the 
subthalamic nucleus that is thought to be excitatory.  
Each spiny neuron cell receives synapses from thousands of distinct cortical 
neurons.  This anatomical organisation is consistent with the idea that spiny cells 
integrate information from many sources (Kincaid et al 1998).  Activity in striatal 
neurons is sensitive to context. This property has been demonstrated by 
experiments where striatal neurons fire in conjunction with a specific movement 
made in one context (e.g. self initiated) but are silent when an identical movement 
is made in another context (e.g. sensorally or memory guided) (Kimura et al 1992).  
The suggestion that the NAc acts as a limbic-motor interface was first introduced by 
Mogenson et al (Mogenson et al 1980). This has been supported by evidence that 
the NAc receives inputs from limbic structures such as the amygdala, hippocampus 
and prefrontal cortex and sends outputs to output nuclei considered primarily 
motor (Nicola 2007), as well as evidence that dopamine injections into the NAc 
increase locomotion (Wu & Brudzynski 1995). The concept of this interface and a 
consequential suggestion that limbic inputs exert an influence on motor output is a 
central concept to this thesis.    
1.2.3 Direct and indirect pathways in the basal ganglia – intrinsic connections 
As well as extrinsic loops linking the basal ganglia to the cortex and thalamus, 
information is also conveyed through intrinsic loops within the basal ganglia. These 
intrinsic loops also maintain a high degree of spatial topography (Redgrave et al 
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2010; Wiesendanger et al 2004). Projections from the striatum to the globus 
pallidus and the substantia nigra maintain a general arrangement throughout these 
intrinsic nuclei. The posterior putamen is primarily engaged in sensorimotor 
functions, the caudate and anterior putamen primarily in associative functions and 
the ventral (limbic) striatum in motivational and emotional functions.  
Within each of these circuits there are two central pathways, referred to as the 
direct and indirect pathways. The GABAergic medium spiny neurons of the direct 
pathway project to the neurons of the GPi and SNr, express substance P and 
dynorphin and preferentially express dopamine D1 receptors. The GABAergic 
medium spiny neurons of the indirect pathway project to the GPe, either directly or 
via the intercalated STN to GPi and SNr (Factor & Weiner 2008).  The neurons of the 
indirect pathway express enkephalin and dopamine D2 receptors (figure I.II.A). 
Emerging evidence suggests that this model, whereby there is a clear differentiation 
between the direct and indirect pathways, as  proposed by Albin et al in 1989 (Albin 
et al 1989) may be too simplistic.  There is now persuasive evidence in support of 
collateral interactions across the system (Matamales et al 2009; Redgrave et al 
2010; Smith et al 1998) and a subgroup of medium spiny neurons which co-express 
D1 and D2 receptors (Aizman et al 2000) (figure I.II.B for expanded model of 
function).  
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Figure I.II.A: Original model of the direct and indirect pathways proposed by Albin et 
al (Albin et al 1989). In this model the output of the basal ganglia is though to be 
modulated by a balance (mediated by dopaminergic inputs from the SNc and VTA) 
between the direct and indirect pathways, which express primarily D1 or D2 
receptors respectively. The direct pathway promoting behaviour and the indirect 
pathway suppressing behaviour via relays in the GPe and STN. 
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Figure I.II.B: More recent anatomical investigations of the basal ganglia reveal 
many more connections which make the responsiveness of the system to inputs 
more difficult to directly predict. (Diagram reproduced from (Redgrave et al 2010)  
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1.2.4  Dopaminergic projections 
The SNc, VTA and the retrorubral field (RRF) provide the main sources of dopamine 
to basal ganglia. The SNc and RRF project to the caudate and putamen and form the 
nigrostriatal system. Neurons arising form the VTA form the mesolimbic and 
mesocortical pathways. In the mesolimbic system, neurons from the VTA project to 
the nucleus accumbens, olfactory tubercle, hippocampus, amygdala and septum 
whereas in the mesocortical pathway,  VTA projects to cortical structures including 
the prefrontal, cingulate and perirhinal cortices (Arias-Carrion & Poppel 2007) 
(figure I.III). As a result of overlap of connections between the ventral striatum and 
the various tiers of the midbrain, the ventral striatum is in a position to influence 
activity in the more dorsal striatal regions, allowing for a limbic influence on  motor 
regions (Haber 2003; Haber & Knutson 2010).  
Dopaminergic inputs functionally regulate the activity of the striatal medium 
projection neurons via interactions with dopamine receptors (see below for more 
detailed discussion of dopamine receptors), and thereby exert an effect on 
corticostriatal transmission. The interaction between the glutamatergic cortical 
inputs and the modulatory dopaminergic projections occurs at postsynaptic 
dendritic spines (Smith & Bolam 1990). The glutametergic terminals converge on 
the head of the dendritic spines whereas the dopamergic terminals converge on the 
neck of the dendritic spines,  providing a mechanism whereby dopaminergic inputs 
filter the more distal glutametergic afferents (Smith & Bolam 1990).  
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Copyrighted Figure removed 
 
Figure I.III: Dopamine projections to the forebrain. Illustrated are projections from 
the ventral tegmental area (VTA) to the nucleus accumbens and prefrontal cortex, 
and projections from the substantia nigra (SNc) to the dorsal striatum (caudate 
nucleus and putamen and related structures) extracted from (Arias-Carrion & 
Poppel 2007) 
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1.3 Biochemistry of dopamine synthesis and action 
1.3.1 Dopamine synthesis  
Dopamine is a catecholamine with its own unique function within the mammalian 
brain. It is also a precursor for noradrenaline and adrenaline (figure I.IV), the other 
two naturally occurring brain catecholamines.   
                                                        
Figure I.IV: Biosynthetic pathway for catecholamines. Reproduced from (Albers et al 
2006). 
 
Once synthesised, dopamine is concentrated in storage vesicles, a high density of 
which are in nerve terminals (Albers et al 2006).  The vesicles are responsible for 
maintaining a steady supply of synaptic catecholamines, by fusing with the 
membrane of the nerve terminal following the influx of calcium caused by an action 
potential   
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There are several factors which determine the duration of dopamine’s action in the 
synapse. The first is the amount of dopamine released, the second is active removal 
of dopamine from the synaptic cleft by dopamine transporters (DAT), and a third is 
activation of presynaptic receptors, known as autoreceptors, which monitor the 
amount of dopamine in the synaptic cleft. When the autoreceptors are activated 
they inhibit synaptic release of dopamine (Koller & Melamed 2007b).   
The metabolism of dopamine is effected by two pathways, both of which involve 
Monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) (Koller & 
Melamed 2007b). Both MAO and COMT act intercelluarly, inactivating the 
catecholamines which are not stored within vesicles, i.e. that are free within the 
nerve terminals. COMT is an enzyme which methylates catecholamines. Its 
expression varies among the normal population due to a common polymorphism in 
which valine is substituted for methionine. The valine polymorphism causes 
increased enzymatic activity and is associated with lower levels of prefrontal 
dopamine, impaired prefrontal cortical function and a reported  increase in risk of 
developing schizophrenia (Albers et al 2006).   
1.3.2 Dopaminergic transmission in the basal ganglia  
The physiological actions of DA are mediated by at least five distinct G protein 
coupled receptor subtypes (Missale et al 1998).  These receptors fall into two 
classes, the D1-like receptor subtypes (D1 and D5) which couple to the G protein 
and activate adenylyl cyclase, and the D2-like receptor subfamily that inhibit 
adenylyl cyclase and activate K+ channels (Berke & Hyman 2000; Ebadi & Pfeiffer 
2005).  In the striatum there is a very high concentration of D1 and D2 dopamine 
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receptors, localised concentrations of D3 receptors in the ventral striatum and 
lower levels of the D4 and D5 type receptors (Bloom & Kupfer 1995).  Unlike the 
excitatory effect of D1 receptor activation, D2 stimulation activates inwardly 
rectifying K+ channels and leads to a decrease in cell excitability (Berke & Hyman 
2000; Koller & Melamed 2007b).  
Striatal D2 receptors are tonically (continuously) stimulated by basal levels of 
dopamine. This tonic activity is important for normal motor behaviour.  Accordingly, 
mice lacking D2 receptors are parkinsonian (Baik et al 1995) in a similar way to 
animals that are given D2 antagonists. Of note, mice bred to lack D1 receptor 
expression do not show parkinsonian symptoms (Drago et al 1994).     
A further important factor is the affinity of the various dopamine receptors for 
dopamine, their substrate. The D1 family of receptors have a low affinity for 
dopamine whereas the D2 like receptors have a high affinity (Creese et al 1983). As 
a result of these differences in affinities it is thought that a high level of phasic 
dopamine release is required for D1 receptor activation, whereas the D2 receptors, 
which have a high affinity for dopamine, are continuously activated by the lower, 
tonic levels of dopamine (Grace 1991).  
Dopamine neurons in vivo have 3 patterns of activity, an inactive hyperpolarised 
state, a tonic (single spike) or a phasic (burst) mode (Grace et al 2007). The tonic 
firing is controlled by an intrinsic pacemaker whereas the burst firing is reliant on 
afferent input. Studies suggest that the neurons of the VTA are held in an inactive 
hyperpolarised state by the ventral pallidum. The ventral pallidum has a high rate of 
spontaneous activity which inhibits VTA dopamine neurons. The release of this 
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inhibition leads to spontaneous firing that provides the baseline levels of 
extrasynaptic dopamine referred to as the tonic level of dopamine (Grace et al 
2007). The burst firing rate is dependent on afferent inputs and this fact has lent 
weight to theories implicating it in reward related and goal directed behaviours 
(Grace et al 2007).      
In addition, D1 receptors have an important role in plasticity whereby activation of 
these receptors leads to long-term potentiation (LTP) and positive reinforcement of 
behaviour  (Reynolds et al 2001). It has been suggested that the positive phasic 
bursting of dopamine neurons activates D1 receptors and induces LTP and long 
term depression (LTD) via D2 receptors, with the reverse occurring when there is a 
pause in dopamine neuron firing (Maia & Frank 2011).  
The D3 receptors are expressed more densely in the limbic striatum then in other 
brain regions, with the NAc and associative striatum showing the highest 
concentration of D3 receptors of all brain regions (Levant 1997). Both dopamine 
agonists, primarily used to treat the motor effects of PD, and the antipsychotics, 
primarily used to treat the affective disorders such as schizophrenia, usually have 
dual action on both the D2 and D3 receptors, stimulating and blocking them 
respectively (Sokoloff et al 1990). Dopamine agonists with high D3 receptor affinity 
have an association with cognitive side effects such as pathological gambling (Dodd 
et al 2005), however dopamine agonists with different receptor affinity profiles can 
also cause cognitive side effects thereby complicating this direct association (Koller 
& Melamed 2007b).     
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1.4 Roles of dopamine  
As detailed above, dopaminergic inputs modulate corticostriatal transmission and 
as such dopamine is a crucial neurotransmitter in the basal ganglia. Dopamine has 
been identified as being involved in many different and partially overlapping 
aspects of behaviour, although the integration of these aspects with one another 
continues to be a subject for debate. One of the central debates surrounds whether 
dopamine cell activity is (i) the driving force behind reward learning; (ii) the 
consequence of learning with its main role being on the expression of learning via 
performance effects, such as modulation of motivated behaviour; or (iii) whether it 
is on a combination of these functions.  
The following is a brief summary of the key behaviours with which dopamine is 
thought to be involved: learning; invigoration of motivated behaviour; movement 
and action initiation. 
1.4.1 Learning  
Dopamine neurons of the VTA and SNc are involved with the processing of 
rewarding stimuli. Dopamine neurons respond with short, phasic activations when 
monkeys are presented with appetitive stimuli.  However when these rewards 
become predicted by a cue, dopamine neurons change the time of their phasic 
activation from time of reward delivery to  time of cue onset (Hollerman & Schultz 
1998; Schultz et al 1997). If the predicted reward is then not delivered, then 
dopamine neuron activity becomes depressed below the basal firing rate at exactly 
the time that the reward should have been delivered. These findings, from the 
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seminal work of Schultz et al (Hollerman & Schultz 1998; Schultz et al 1997), 
demonstrate that rather than simply signalling rewards, dopamine neurons code 
for a difference between the expected and delivered reward, in other words the 
‘prediction error’ (Schultz et al 1997) (figure I.V).  
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Figure I.V: Represented in this figure are the seminal neurophysiological results of 
Schultz et al. The top panel shows midbrain dopamine neuron activity before 
learning takes place when a monkey is given a drop of unexpected appetitive juice. 
At this point there is no prediction so the activity in the midbrain dopaminergic 
neurons report a positive prediction error when the reward is delivered. The middle 
panel shows dopamine neuron activity when learning has taken place. Now the 
dopamine cell firing occurs at the same time as the cue predicting the reward and 
therefore when reward delivery is fully predicted the dopamine neurons are not 
activated by the delivery of reward. The bottom panel shows dopamine neuron 
activity after learning has taken place. As in the middle panel, when the reward- 
predicting cue is presented, dopamine cell activity increases.  When the predicted 
reward subsequently fails to be delivered, however, there is a dip in firing at exactly 
the time when the reward should have been delivered (negative prediction error) 
(taken from (Schultz et al 1997)). 
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It has also been highlighted that the prediction error response resembles the 
‘teaching signal’ derived from computational reinforcement learning theory (the 
Rescorla-Wagner learning model) (Moll et al 1999; Schultz 2010; Schultz et al 1997), 
providing further support for its role in guiding learning via synaptic plasticity 
(Centonze et al 2001; Maia & Frank 2011). Experimental evidence linking dopamine 
to reward learning is extensive (Bayer & Glimcher 2005; Hollerman & Schultz 1998; 
Schultz et al 1997; Wise 2004; Wise & Rompre 1989) and much work supporting a 
role for dopamine signalling error prediction has emerged (Montague et al 2004; 
Schultz et al 1997).   
The behaviour of dopamine neurons in response to predicted and surprising 
rewards, as described above, has been widely replicated.  The proof, however, that 
this is the critical signal which drives learning and causes “stamping in” of stimulus-
cue and stimulus-response associations is more controversial (Berridge & Robinson 
1998). Contributing to the controversy are studies in which dopamine deficient 
mice have been shown to have no deficits in learning in response to rewards and 
they are capable of picking the most rewarding drink (sucrose compared with 
water) when presented with both (Cannon & Palmiter 2003). Other evidence 
against dopamine being required for learning has come from work on genetically 
dopamine deficient mice which show that although learning in a maze task 
appeared initially impaired in this group, when they were subsequently treated 
with L-dopa (Robinson et al 2005), or caffeine (Hnasko et al 2005) these lesioned 
mice had learned, an effect one can frame as demonstrating an effect of dopamine 
on the expression of learning rather than on learning itself.   
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There have been several studies demonstrating a boosting of reward prediction 
errors and differences in learning rates in hypo-, hyper- and normal dopaminergic 
states (Pessiglione et al 2006; Voon et al 2010). This is in contrast to the results of 
experiments on hyperdopaminergic mutant mice who show no difference in the 
speed of action-outcome learning (Yin et al 2006), In one of these studies however, 
the hyperdopaminergic rats pressed the lever more frequently than the normal rats 
in order to obtain rewards, a fact attributed to dopamine having an effect on 
performance rather than learning (Yin et al 2006).  
As a consequence of these, and other findings, it has been suggested that the firing 
of dopamine neurons, rather than acting as a teaching signal which enhances 
learning, may instead be an actual consequence of learning which takes place 
elsewhere in the brain. These theories suggest that instead, dopamine serves to 
attach ‘incentive motivation’ to learned cues (Berridge 2007), which has been 
defined as “a conditioned motivation response of a brain, usually triggered by and 
assigned to a reward-related stimulus”(Berridge 2007; Berridge & Robinson 1998). 
1.4.2 Motivation and vigour 
It has been proposed that tonic dopamine levels are involved in controlling 
movement rate and vigour (Salamone & Correa 2002; Ungerstedt 1971). Dopamine 
has been shown to be involved with motivational engagement and vigour (Bardgett 
et al 2009; Berridge & Robinson 1998; Boureau & Dayan 2011; Lex & Hauber 2010; 
McClure et al 2003b; Niv 2007; Niv et al 2007), with dopamine depletion causing 
decreased motivation to work for rewards when reinforcement schedules are 
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demanding (Niv 2007; Salamone & Correa 2002) and, conversely,  invigorating 
actions when dopamine levels are high (Salamone et al 2005). 
Dopamine levels have been shown to be involved in determining the amount of 
effort an animal is prepared to make to obtain a reward and to have an effect on 
the rate of responding (Niv 2007; Salamone et al 2003). These findings fit with 
theories derived from computational neuroscience which suggest that this pattern 
reflects the net rate of environmental rewards being signalled by tonic dopamine 
levels. Thus, in a high tonic dopamine state, a high net rate of environmental 
reward is signalled and consequently every second during which a reward is not 
reaped is more costly (a cost of sloth) making it worthwhile for subjects to perform 
actions quickly even if the energetic cost is higher (Niv 2007; Niv et al 2007). The 
incentive salience point of view fits  with this account as according to this theory 
dopamine is involved with the attachment of motivational properties to rewarding 
cues (Berridge 2007). 
1.4.3 Action selection and movement  
Finally, it is clear that dopamine plays a key role in action selection and movement, 
although precisely how this function operates is still subject of debate.   
A popular model for this is the actor-critic model (Joel et al 2002; O'Doherty et al 
2004). In this model the cortex is thought to represent the current state and the 
basal ganglia implements two computational roles – the ‘critic’ (presumed to be 
implemented in the ventral striatum and possibly in the PFC and amygdala) which 
learns the values of outcomes and the ‘actor’ (presumed to be implemented in the 
dorsal striatum) which learns stimulus-response associations so that actions 
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associated with long term rewards are subsequently chosen more frequently, with 
both regions updating their estimates based on dopaminergic prediction errors.  
A different view is that the basal ganglia arbitrate between actions that are under 
consideration by the cortex so as to facilitate the best one based on learnt 
reinforcement probabilities (learnt action values) (Samejima et al 2005).   
Another important factor when considering the modulatory functions of dopamine  
is the relative influence of phasic versus tonic dopamine, with phasic dopamine 
neuron activity being associated with learning from rewards by enhancing Go 
activity via  low affinity D1 receptors and conversely tonic dopamine dips driving 
NoGo behaviour via the high affinity D2 receptor stimulation when there are pauses 
in firing (Bayer & Glimcher 2005; Frank et al 2007; Frank et al 2004; Maia & Frank 
2011).  It has been proposed that they work in concert to obtain rewards, with D1 
receptors being stimulated by phasic firing and, at the same time, D2 receptors 
being stimulated by tonic dopamine thereby reducing activity in the NoGo pathway 
which allows facilitation of reward directed behaviours (Hikida et al 2010).  
What is clear from the above discussion is that no overall consensus has as yet 
emerged regarding the precise nature of the influence of dopamine on behaviour.  
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1.5 Serotonin and behaviour 
Many neurotransmitters aside from dopamine are involved in cognition, however 
much research has focussed on a central role for serotonin, especially in the 
modulation of aversive learning and decision making. However, the way in which 
serotonin influences behaviour is complex. Part of this complexity arises from 
studies which have demonstrated that both medications which reduce serotonin 
transmission, such as benzodiazepines (Deakin & Graeff 1991), and the chronic use 
of medications which increase serotonin concentrations, such as selective serotonin 
reuptake inhibitors (Hollander 1998), have anxiolytic effects. Indeed both class of 
drugs are effective in treating disorders such as anxiety and depression which are in 
turn associated with increased aversive processing (Cools et al 2008a).   
Furthermore, acute tryptophan depletion, a procedure which reduces levels of 
serotonin, has been shown to increase BOLD activity in response to punishment 
prediction but to have no effect on reward predictions (Cools et al 2008b). It has 
been suggested that serotonin might impact punishment prediction errors much in 
the way that dopamine has been proposed to impact positive prediction errors 
(Daw et al 2002).  
As is the case with dopamine, serotonin has effects on behavioural inhibition and its 
depletion has been shown to worsen behavioural responses to stimuli which 
require motor inhibition. In addition, serotonin depletion has been shown to impair 
acquisition in a conditioned visual discrimination task (Harrison et al 1999), thereby 
having effects on both learning and performance.  
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The various roles of serotonin and their interactions with dopamine are still not 
fully understood. There remain several paradoxes such as serotonin depletion being 
implicated in diseases characterised by impulsivity and reduced aversive processing 
while also being central in diseases such as depression characterised by reduced 
behavioural vigour and enhanced aversive processing (Cools et al 2011).   
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1.6 Parkinson’s disease   
1.6.1 Neuroanatomy of Parkinson’s disease 
Parkinson’s disease is a progressive degenerative neurological disorder 
characterised by asymmetric onset of tremor, rigidity and bradykinesia (Pavese & 
Brooks 2009). It is one of the most common neurological disorders with prevalence 
rates standing at 1.8% in people over the age of 65 (de Rijk et al 2000). The cardinal 
pathological feature of PD is loss of pigmented neurons in the substantia nigra pars 
compacta leading to decreased levels of dopamine in the striatum (Koller & 
Melamed 2007b). The SNc does not directly participate in the transfer of 
information along the basal ganglia thalamocortical pathways, but is part of the 
brainstem catecholaminergic systems, providing dopaminergic inputs to striatum 
and other targets (Koller & Melamed 2007b). 
The pattern of degeneration in PD is uneven with the posterior putamen and 
ventrolateral substantia nigra being affected first (Cools 2006; Pavese & Brooks 
2009).  Fluorodopa PET imaging has revealed that the largest uptake reduction is in 
dorsal posterior putamen  
contralateral to the side of maximal clinical symptom expression (Morrish et al 
1995) (figure VI).  
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Figure VI: Schematic to show the progession of dopamine cell degeneration in PD. In 
PD there is a spatio-temporal progression of dopamine (DA) cell degeneration from 
the ventral tier to the dorsal tier of the midbrain (which includes the VTA). The dark 
blue to light green shading gradient represents the spatio-temporal progression of 
pathology from dorsal to ventral fronto-striatal circuitries over the course of the 
disease. The ventral tier which is severely degenerated in PD sends DA projections 
primarily to the dorsal striatum, which projects to relatively restricted portions of 
the more dorsal and lateral parts of the PFC (Alexander et al., 1986). The relatively 
intact dorsal tier sends DA projections primarily to the ventral striatum, which 
projects via the output nuclei of the basal ganglia and the thalamus to ventrolateral 
and ventromedial PFC. Reproduced from (Cools 2006). 
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In PD, the external appearance of the brain is usually unremarkable (Factor & 
Weiner 2008; Koller & Melamed 2007a) and there is no significant atrophy of the 
midbrain however in some cases there is frontal atrophy (Factor & Weiner 2008). 
However PD is more prevalent in older individuals and age is associated with 
anatomical shrinkages of cortical and subcortical regions (Raz & Rodrigue 2006). 
The cardinal pathology in idiopathic PD consists of formation of interneuronal lewy 
bodies, which are eosinophilic inclusion bodies, composed mainly of misfolded α-
synuclein, a 140-amino-acid protein which is a normal constituent of the 
presynaptic apparatus (Braak et al 2004; Koller & Melamed 2007b; Pavese & Brooks 
2009). The Lewy bodies can be detected in the lower brainstem before midbrain 
and nigral involvement. Braak et al have proposed a six point staging system for the 
pathological process in PD. According to this scoring system, during the 
presymptomatic stages (Braak stage 1-2) the Lewy bodies and Lewy neurites are 
confined to medulla oblongata/pontine tegmentum and olfactory bulb/anterior 
olfactory nucleus, as well as affecting the medullary raphe nuclei and locus 
coeruleus which are rich in noradrenergic neurons. In stages 3-4 the substantia 
nigra and other nuclear groups of midbrain and forebrain become affected, and this 
is usually accompanied by the appearance of clinical symptoms. Finally in stages 5-6 
Lewy bodies also appear in the neocortex (Braak et al 2004).    
Advanced stages of idiopathic PD are associated with grey matter volume decrease 
in the BG and smaller substantia nigra volumes on volumetric Region ROI analysis 
on T1 images. Also with the use of probabilistic diffusion tractography it has been 
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demonstrated that IPD patients have lower connectivity probability between 
substantia nigra and putamen/thalamus (Draganski & Bhatia 2010). 
The essential pathophysiological characteristic of the PD state, as a result of the 
neuronal damage, is increased neuronal firing activity in the output nuclei of the 
basal ganglia (globus pallidus pars interna (GPi) and substantia nigra pars reticulata 
(SNr)) leading to excessive inhibition of thalamocortical and brainstem motor 
systems (Obeso et al 2008), with subsequent development of Parkinsonism (Pavese 
& Brooks 2009). In the parkinsonian state there is decreased excitation in the D1-
bearing or ‘direct’ pathway and increased activity in the D2 dopamine receptor 
expressing, or ‘indirect’ pathway (Obeso et al 2008).   
1.6.2 PD as a model of dopamine depletion - limitations 
As PD is characterised by dopaminergic cell loss it provides a model of the effects of 
dopamine depletion in humans. However it is not only the dopaminergic system 
which is affected by the pathological processes occurring in PD and due to the 
reciprocity of the relationship between dopamine and other neurotransmitters, 
dopamine depletion cannot occur in isolation. The >80% loss of dopamine in the 
striatum in PD is accompanied by a 50% decrease in 5HT/serotnonin levels (Wilson 
et al 1996). Anatomical data on the 5-HT connectivity within the basal ganglia 
indicates that 5-HT is in a position to modulate function by interacting with 
dopamine systems both at the level of substantia nigra and at the striatum. It is 
thus likely that abnormalities in 5-HT transmission may contribute to the neural 
mechanisms of PD and complications associated with long-term treatment with 
levodopa (Hornykiewicz 1998; Nicholson & Brotchie 2002). 
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In fact the pigmented neurons of the primarily adrenergic locus ceruleus undergo a 
similar process of neurodegeneration to that seen in the SNc (Koller & Melamed 
2007a). Cholinergic cell loss in the basal nucleus of Meynert and the 
pedunculopontine nucleus and serotinergic cell loss from the raphe nucleus also 
occurs in PD (Factor & Weiner 2008) as is also described in the Braak staging (Braak 
et al 2004). In view of the perturbation of other neurotransmitter systems it is likely 
that some of the deficits observed in this patient group may be due to these other 
neurotransmitter abnormalities.  
PD is also a disease more common in older individuals, another factor which 
becomes important when testing this group of patients. Concurrent with the 
anatomical shrinkages observed in older individuals, the efficacy of various 
neurotransmitter systems, including the dopaminergic, serotinergic, cholinergic and 
noradrenergic systems are also compromised by ageing (Eppinger et al 2011). There 
is age related loss of both the striatal D1 (Suhara et al 1991) and D2 (Antonini et al 
1993) receptors and of the dopamine transporter DAT (Erixon-Lindroth et al 2005). 
The average decline ranges between 5% and 10% per decade from early to late 
adulthood (Eppinger et al 2011). These differences lead to difficulties when 
comparing subjects of different ages. However, if a smaller age range is enforced on 
the experimental group tested, then the generalisation of results to the whole 
population of PD patients becomes problematic.   
In addition, Parkinson’s disease is a very heterogeneous disorder with wide ranging 
clinical phenotypes. It is therefore difficult to make inferences in these patients 
across groups and specifically to compare them one with another. In my first study 
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(chapters 3 and 4) I employed a within subject design in order to avoid the need to 
match different individuals with PD with each other and in the second experiment 
(chapter 5) I matched PD patients with controls. Although these strategies address 
some of the difficulties, it still remains difficult to make inferences about the wider 
population of PD sufferers from small samples.  
Nevertheless, despite the many difficulties involved in studying PD patients, this 
group of patients provides the only disease model of dopamine depletion in 
humans and therefore by studying PD patients in complex cognitive tasks we can 
gain further insight into some of the cognitive difficulties these patients face and 
facilitate increased understanding of the possible neurobiological mechanisms 
behind these deficits.    
 
1.6.3 Mechanism of action of Levodopa and dopamine agonists 
In the next section I will discuss the cognitive sequelae of the treatment of 
Parkinson’s disease. In order to provide a background for this discussion, in the 
following section I provide a brief overview of the mechanism of action of Levodopa 
and dopamine agonists.   
The mainstay of treatment for PD aims to counteract the depleted dopamine levels 
caused by the disease, either by replenishment or by symptomatic relief of the 
consequences of this depletion. There are several pharmaceutical methods which 
can be used to this end. The gold standard of symptomatic therapy remains oral 
administration of Levodopa (L-dopa) (Koller & Melamed 2007b). L-dopa is the 
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precursor of dopamine and as opposed to dopamine itself, can easily cross the 
blood brain barrier. It must be administered in a formulation along with a 
peripheral aromatic-amino-acid de-carboxylase inhibitor (AADI) in order to 
minimise its breakdown in the extracerebral tissues. AADI’s do not cross the blood 
brain barrier and therefore do not affect conversion of dopamine in the brain 
(Koller & Rueda 1998; Pahwa et al 2003).  
Once Levodopa has crossed the blood brain barrier it is converted to dopamine and 
then stored in synaptic vesicles for subsequent release (Ebadi & Pfeiffer 2005).  This 
is the case in early PD , and in the healthy brain,  so that administration of levodopa 
at this stage is more likely to mimic the phasic physiological role of dopamine 
(Factor & Weiner 2008). Later in the disease progression however, with the further 
loss of presynaptic dopaminergic neurons and/or with excessive doses, levodopa 
may also be converted to dopamine in nondopaminergic neurons leading to loss of 
normal physiologic control of dopamine release (Factor & Weiner 2008).  The 
antiparkinsonian effect of levodopa is predominantly due to stimulation of the D2 
receptors. D2 postsynaptic receptors and presynaptic autoreceptors have almost 
contrasting functions, and it is thought that the activation of postsynaptic D2 
receptor is what exerts the effects of dopamine on motor behaviour (Factor & 
Weiner 2008).  Although L-dopa is the most effective symptomatic therapy, it has 
drawbacks including the development of motor fluctuations and dyskinesias 
associated with chronic use as well as neuropsychiatric disturbances (Ebadi & 
Pfeiffer 2005).      
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Another important treatment option, utilised especially in early PD or as an adjunct 
to levodopa, are dopamine agonists.  Dopamine agonists interact directly with the 
dopamine receptors and different agents have different affinities for dopamine 
receptor subtypes, with the most commonly used agents such as ropinirole and 
pramipexole having mainly D2/D3 receptor affinity (Koller & Melamed 2007b). 
Given their different receptor affinities, it might be expected that the different 
agents have different clinical effects but this has not yet been clearly established in 
the literature (Koller & Melamed 2007b).  
We manipulated these chemical treatments in order to elucidate specific 
mechanisms for the actions of dopamine. In our experiments, as with the majority 
of drug manipulations in PD patients performing tasks seeking to elicit the effect of 
DRT (Dopamine replacement therapy) on performance, the ‘washing out’ period  
involves a minimum of a 12 hour withdrawal from all DRT, and omission of all long 
acting levodopa preparations within 24 hours. As most patients are treated with 
adjunct agents to the levodopa it is possible that some of the effects of medication 
withdrawal in the studies found in the literature, and in the first two experiments 
described in this thesis, are attributable to therapy with these other agents which 
also have a longer half life, with most dopamine agonist having a half life of 
between 6-20 hours (Koller & Melamed 2007b). Unfortunately due to recruitment 
difficulties it was not possible for us to recruit patients who were on levodopa alone 
a factor likely to reflect current prescribing patterns. 
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1.6.4 Cognitive deficits in PD and effect of LDOPA on these deficits 
Although initially PD was primarily recognised as a movement disorder, recent 
evidence points to widespread cognitive involvement even in non-demented and 
non-depressed PD patients with cognitive deficits being observed even in the early 
stages of the disease (Lees & Smith 1983) . These cognitive deficits broadly 
resemble those observed in patients with frontal lobe damage and include deficits 
such as attentional and working memory deficits (Cools 2006; Dubois & Pillon 1997; 
Lees & Smith 1983; Owen et al 1992). The CamPaiGN study demonstrated that 36% 
of PD patients performed poorly in at least one of three cognitive tasks 
(Mini‐Mental State Examination, a pattern recognition task, and the Tower of 
London task) (Foltynie et al 2004) and even early, drug naïve PD patients were 
found to have double the rates of mild cognitive impairment when compared to 
controls (Aarsland et al 2009). From the follow up of the PD patient cohort in the 
CamPaiGN study it also became evident that dementia in PD was related to 
variations in tau haplotype while the frontal-executive dysfunction observed 
appeared more dopaminergic in basis and had a better prognosis (Williams-Gray et 
al 2009). 
As discussed above, the dopamine cell degeneration is not uniform across the 
midbrain with the SNc and dorsal striatum being particularly sensitive to neuronal 
degeneration (Pavese & Brooks 2009). The main projection structures of the dorsal 
striatum include the motor and pre-motor cortices, the supplementary motor areas 
and the dorsolateral PFC (Alexander et al 1986). The VTA and ventral striatum with 
their projections to the orbitofrontal cortex (OFC), the amygdala and the anterior 
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cingulate cortex (ACC) and inferotemporal cortex, are less affected early in the 
disease (Cools 2006).  
The gold-standard of treatment of PD is replacement of depleted dopamine levels 
with levodopa. Younger patients however are generally commenced on other types 
of therapy such as dopamine agonists or MAO inhibitors in order to allow the 
commencement of levodopa to be postponed. The reason for this is that prolonged 
treatment with levodopa can lead to increased motor fluctuations and dyskinesias 
(Factor & Weiner 2008).  
It appears the relationship between dopamine and performance in many cognitive 
tasks, especially working memory tasks (Stuss & Knight 2002a), follows an inverted 
U-shaped function whereby the optimum level of performance exists at a certain 
level of dopaminergic stimulation and moving off that peak, either by reducing or 
increasing the levels of dopamine leads to worsened task performance (Cools 2006; 
Williams & Goldman-Rakic 1995). It has been proposed that this optimum level 
differs between different cortico-striatal circuits, and therefore by increasing or 
decreasing the optimum level in one circuit, there might be a movement away from 
the optimum in different circuit. For example dopaminergic modulation with L-dopa 
in PD patients may move subjects to their motor optimum but away from their 
cognitive optimum (Gotham et al 1988; Rowe et al 2008).     
It has been noted in several studies that performance on cognitive tasks while ON 
and OFF medication varies between different individuals with PD. There are several 
hypotheses explaining this observation. The first, proposed by Gotham et al 
(Gotham et al 1988)  explains the individual variation in performance to be due to 
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differences in individual baseline dopamine levels causing some circuits in the 
striatium to have adequate dopamine levels while others become putatively 
‘overdosed’ by the DRT (Gotham et al 1988). A different hypothesis proposed by 
Kulisevsky et al (Kulisevsky et al 1996), spurred by the finding that patients with 
different responses to dopaminergic medication (stable vs fluctuating ON and OFF 
periods) had different performance in cognitive tasks when ON and OFF levodopa, 
they proposed that the performance differences reflected differences in sensitivity 
to plasma levodopa concentrations due to supersensitivity of neurons to dopamine 
receptor stimulation (Kulisevsky et al 1996).  
As mentioned above, PD results in deficits across several cognitive domains, 
including probabilistic learning and classification tasks (Graef et al 2010; Knowlton 
et al 1996), with dopamine replacement therapy (DRT)having distinct effects on 
these behaviours.  
For example, in probabilistic reversal learning tasks, medication can impair 
performance in reversals, specifically those that are signalled by negative feedback 
(Cools et al 2006; Cools et al 2001a) but can improve task switching (Cools et al 
2001a). This pattern has been attributed to an appropriate dopamine replacement 
of the dorsal striatal circuitry involved in task switching while ‘overdosing’ the 
relatively spared ventral striatal circuitry involved in reversal learning (Cools et al 
2001a; Cools et al 2007a).  
In reinforcement learning paradigms when PD patients are OFF DRT, the expression 
of learning from positive feedback is impaired. Conversely, when ON DRT they show 
impaired performance in learning from negative outcomes (Bodi et al 2009; Frank 
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et al 2004). This behavioural pattern has been attributed to increased levels of 
striatal dopamine, when patients are ON their DRT, boosting prediction error 
signals resulting in enhanced learning from positive outcomes. By contrast, a 
prevention of dips in dopaminergic activity, as observed with omission of expected 
outcomes, is suggested to worsen learning from negative outcomes (Frank et al 
2007; Frank et al 2004; Maia & Frank 2011). In other words, we see that 
performance in these and many other cognitive tasks can either be ameliorated or 
worsened by DRT, leading to a complex picture of the function of dopamine in 
cognition.  
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Chapter 2  
Methods  
 
The following chapter reviews the methodology used in the experiments described 
in the next chapters. 
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2.1 Functional Magnetic Resonance imaging (fMRI); Physical 
principals 
2.1.1 Magnetic resonance imaging (MRI): basic principals 
Magnetic resonance imaging (MRI) is a non-invasive imaging technique which 
utilises the magnetic properties of atoms in order to create detailed images of 
internal organs. 
2.1.1.1 Spin and radiofrequency pulse 
Protons along with neutrons and electrons compose atoms which together 
comprise all matter.  Neutrons and protons form the atomic nucleus and different 
atoms have different nuclear compositions. Under normal conditions protons spin 
on their axis due to thermal energy. The motion of spinning generates an electrical 
current on the surface of the proton which in turn creates a small magnetic source 
when it is placed within a magnetic field. The strength of this magnetic source is 
called the magnetic moment. When protons have an odd numbered atomic mass 
(as in the hydrogen atoms) the spin results an angular momentum (Huettel et al 
2009). 
A nucleus must have both a magnetic moment and an angular momentum for it to 
have a nuclear magnetic resonance property (NMR), and if a nucleus does not have 
both these properties it cannot be studied using magnetic resonance. Due to the 
high water content in the human body, hydrogen protons which have NMR 
properties, are abundant. In the absence of a magnetic field the spin axis of protons 
are orientated randomly and tend to cancel each other out leading to a very small 
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net magnetisation. To increase the net magnetisation of protons a strong magnetic 
field is applied which aligns the axis of the protons.  
When protons are in a strong magnetic field, they make a gyroscopic motion 
around their aligned axis’ which his known as precession. The precession frequency, 
known as Larmor frequency, is determined by the type of nucleus.  Protons can 
precess in either a parallel  or an antiparallel state to the magnetic field, where 
protons in the parallel state have lower energy then protons in the antiparallel state 
(figure II.I).   
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Figure II.I: Magnetic field causes the alignment of nuclei that have the NMR 
property. (a) When no external magnetic field is present protons have their spin axis 
aligned randomly. (b) When a strong magnetic field is introduced protons tend to 
align their axis either parallel or anti-parallel to the magnetic field. More of the 
spins will enter the parallel state resulting in a net magnetisation parallel to that of 
the scanners’ magnetic field.  Reproduced from (Jezzard et al 2003). 
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Magnetic resonance techniques measure the net magnetisation of all nuclei in a 
volume and the magnitude of this is determined by the difference between the 
number of spins in the parallel and antiparallel states, the more spins in the parallel 
state, the bigger the net magnetisation. One way to increase the proportion of 
parallel spins is to reduce the temperature, though this method is impractical for 
human imaging. Another way of increasing net magnetization is to increase the 
strength of the external magnetic field.  
In order to generate an MR signal however, one must pertubate the equilibrium 
state of the spins and then observe how they react to this perturbation. Transitions 
between the low and the high energy states can be triggered by the delivery of 
energy to the spin system. Radiofrequency coils bombard spins in the magnetic 
field. The distribution of spins between the low and the high energy states is altered 
by the delivery of this energy, favouring transitions between the more abundant 
(typically the parallel low energy state) to the less abundant (typically the anti-
parallel high energy state), a process known as excitation. When the amount of 
excitation required to create equal numbers of nuclei of each energy state is 
delivered, the net magnetisation is flipped form the longitudinal to the transverse 
axis where the measurable MR signal is greatest. When the electromagnetic waves 
are turned off, the excitation of the nuclei stops and due to the disruption of the 
thermal equilibrium due to excitation, the excess spins at the high energy level 
must return to the lower level to restore equilibrium. When these high energy spins 
fall back to the low energy state they emit photons and the energy in these photons 
is equivalent to the difference between the two states. The changes in 
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magnetisation can be detected using a radiofrequency coil and the changing 
current in these detector coils constitute the MR signal. From the excited state 
there are two forms of relaxation: 
T1 relaxation 
The T1 relaxation time is the time taken for the spin system to lose energy and for 
the net magnetisation to become re-aligned along the longitudinal axis. The T1 
relaxation time influences the rate at which MR images can be collected as it 
renews the longditudinal magnetisation so it can be excited again.  
T2 relaxation 
T2 relaxation is the time taken for the decay of the transverse component of the 
net magnetisation to occur due to spins becoming out of phase with each other, 
and the T2* time is the cumulative effect of T2 time plus the effect of the magnetic 
field inhomogeneities and is therefore shorter then the T2 time. T2 relaxation has 
the effect of reducing the overall net magnetisation in the transverse plane. 
Depending on when the image is acquired during the relaxation process determines 
the intensity of the image. The BOLD contrast in fMRI relies on the T2* contrast 
(Huettel et al 2009).  
2.1.1.2 Frequency and phase encoding 
In order to be able to differentiate between different structures, the spin 
precession frequencies need to change over space. Frequency encoding allows the 
construction of a one dimensional map of proton density along the gradient due to 
the introduction of another magnetic gradient. By applying this extra gradient there 
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will be extra oscillations imposed on the precessions that are ongoing, causing 
different precession speeds for different protons dependant on where they are in 
space. The information gathered from this process can be used to map distances 
between structures that are being imaged. 
Phase encoding refers to the application of another gradient within a slice in a 
sequential manner to allow for the formation of a three dimensional MR image. The 
phase encoding gradient is applied before the data acquisition so that the spins are 
precessing at different rates depending on their spatial location. So when the extra 
frequency encoding gradient is introduced they will already differ in their current 
angle of precession (their phase). In fMRI data acquisition the pulse sequences are 
very fast and the two gradients alternate rapidly during data acquisition. By 
recording the signal many times following many different combinations of gradients 
it is possible to effectively estimate the density and distribution of the nuclei of the 
object being imaged (Huettel et al 2009). 
2.1.1.3 Voxels 
The basic sampling unit of MRI are known as voxels, or volume elements. All MRI 
images of the brain are in three dimensions and voxels represent a quantity of 3D 
data in the images. Theoretically, the best imaging technique would have a high 
spatial and temporal resolution while minimising the signal to noise ratio. These 
factors are however at odds with each other. High spatial resolution can be 
achieved by reducing the voxel size due to the fact that small voxels allow for better 
anatomical localisation. This however comes at a price due to the fact that  the total 
signal recovered from a voxel is proportional to its size. Therefore if voxels are too 
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small there may be insufficient signal to create high quality images thereby 
degrading the signal to noise ratio. A further complicating factor is as the voxel size 
gets smaller the total amount of voxels in the image increases thereby lengthening 
the imaging time required to collect the necessary information which in turn will 
affect the temporal resolution of the data collected (Buxton 2009). The voxel size 
acquired in the first experiments in this thesis (chapters 3 and 4) was 2x2x2mm and 
in the third (chapter 6) are of the order of 3x3x3mm. 
2.1.1.4 Image contrast 
In order to differentiate tissues from one another, it is possible to exploit the 
different relaxation time properties present in different tissues. Other methods for 
achieving this goal include injection of contrast agents, relying on changes in 
physiology altering magnetic properties or sensitising the images to blood flow or 
molecular diffusion. Here I will discuss only the contrast achieved by exploiting the 
differences in relaxation times. By altering two of the sequence timing parameters, 
the time between radiofrequency pulses (TR) and the time to echo following the 
excitation pulse (TE), which is the time taken for the transverse magnetisation to 
decay, it is possible to achieve relaxation time contrast. By shortening the TR so it is 
less then the T1 relaxation time (the time it takes the longitudinal magnetisation to 
completely recover) it is possible to achieve T1 weighted images. For example at 3 
Tesla, fluid has a long T1 relaxation time (over 3sec) whereas white matter has a 
much shorter one (approximately 800ms) giving an image where fluid is dark and 
white matter a light grey. By manipulating the TE time, regions which lose their 
transverse magnetisation quickly will have a lower signal whereas regions with 
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longer T2 relaxation time such as fluid, will appear brightest.  For a more extensive 
review see (Jezzard et al 2003). 
2.1.2 Functional magnetic resonance imaging (fMRI): basic principals 
2.1.2.1 BOLD contrast in fMRI 
The metabolic consequences of neuronal activity provide the BOLD (Blood-
oxygenation-level dependant) contrast used in fMRI. Neurons which are active 
require more oxygen to metabolise increased amounts of glucose, and 
consequentially this will cause an increase in levels of deoxygenated blood. 
Oxygenated and de-oxygenated blood, have different magnetic properties. When 
haemoglobin is oxygenated it is diamagnetic (weakly repulsed from a magnetic 
field), and when it is deoxygenated it is paramagnetic (attracted to a magnetic 
field). In the early 1980’s it was experimentally verified by Thulborn et al (Thulborn 
et al 1982)  that when the magnetic field strength was high (over 1.5 Tesla) there 
were differences between the transverse relaxation of oxygenated and 
deoxygenated blood.  
This fact was exploited in seminal work by Ogawa et al (Ogawa et al 1990a; Ogawa 
et al 1990b), when it was demonstrated that by using gradient echo techniques it 
was possible to accentuate the susceptibility effects of deoxyhaemoglobin in 
venous blood. Since those initial experiments it has become evident that the BOLD 
response depends not only on blood oxygenation but on cerebral blood flow and 
volume. For a full review see (Logothetis 2003). 
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2.1.2.2 Neurophysiology of BOLD signal 
The MR signal change triggered by neuronal activity is known as the haemodynamic 
response, and this response is dependant on the amount of deoxygenated 
haemoglobin over time. It is shaped not only by the extraction of oxygen by active 
neurons but also on changes in blood flow and blood volume. When neuronal 
activity increases, so does cerebral blood flow, providing an increase in the amount 
of oxyhaemoglobin which is actually greater than that which is required for 
neuronal activity. As the proportion of deoxyhaemoglobin compared to 
oxyhaemoglobin decreases due to the increase in cerebral blood flow, the BOLD 
fMRI signal increases, therefore the BOLD signal reflects the increase in cerebral 
blood flow to the active neuronal area rather than a direct measure of 
deoxygenated blood. Data from animal work in which simultaneous fMRI and 
neurophysiological recordings were undertaken have demonstrated that the fMRI 
BOLD signal correlates most closely with local field potential readings, and has been 
interpreted as meaning that BOLD more closely reflects inputs to an area rather 
than neuronal spiking activity (Logothetis et al 2001) .  
The spatial resolution of fMRI studies is generally good, though it depends in part 
on voxel size. As mentioned earlier, the larger the voxel size the worse the spatial 
resolution. However if voxel size is decreased too much, the signal to noise ratio will 
go up, and as well as this the slice acquisition time will need to increase. However, 
BOLD is an indirect measure of neural activity and therefore another factor 
affecting spatial resolution in fMRI studies is the differences in vasculature between 
different areas. Because of changes in blood flow, when large amounts of 
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oxygenated blood flow into areas with increased neuronal activity, the proportion 
of oxygen extracted by neurons decreases causing the amount of oxygenated blood 
entering the draining venous system to increase which in turn can cause draining 
vessels which may be relatively distant from the area of neuronal activation, to 
show BOLD signal changes. 
Another factor affecting spatial resolution is the variability in individual anatomy 
between different subjects. The preprocessing stages detailed below increase the 
functional resolution of the data but at the same time reduce the spatial resolution. 
fMRI has an intermediate level of temporal resolution, less then that afforded by 
recordings from microelectrodes which can record the firing of a single neuron as it 
occurs but better than afforded by other approaches such as PET or lesion studies.  
Although cortical neuronal responses occur within tens of milliseconds following a 
sensory stimulus, the haemodynamic change does not commence until 1-2 seconds 
later. The fMRI BOLD haemodynamic response rises and falls over a period of 
approximately 10 seconds and so we need to estimate neuronal activity based on 
these slower changes in the vascular system (figure II.II).  
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Figure II.II: The BOLD impulse response. The peak occurs at 4-6 seconds followed by 
an undershoot of 10-30 seconds. In high magnetic fields an initial undershoot may 
also be present. Image taken from (Henson 2008) 
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2.2 Functional Magnetic Resonance imaging (fMRI); 
Statistical analysis 
2.2.1 Pre-processing 
During an fMRI experiment, data from the 3D matrix of voxels is resampled over 
time so that every voxel will have numerous time points. Over time however, there 
will be head movements which can have a large influence on the data acquired and 
cause difficulty when trying to align voxels with each other, which is a necessary 
step in order to be able to make statistical inferences about the data as a whole. It 
is therefore necessary to apply preprocessing algorithms to the data in order to 
remove uninteresting variability prior to formal statistical analysis.  
Below is an image depicting the different stages of preprocessing of fMRI data 
(figure II.III). The stages involved in preprocessing are in the red box below. In the 
first stage, the images are realigned to adjust for movements between slices. 
Following this, in the functional-structural co-registration stage the functional and 
structural images are linked by overlaying one on the other. The next stage is called 
normalisation in which the images are warped until they are in standard MNI space 
(which is an average template over many normal brains) and finally the images are 
smoothed in order to increase signal to noise ratio.  Further details of each stage 
are provided below.  
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Figure II.III: The stages of fMRI data analysis. The stages involved in preprocessing 
are in the red box. The stages in which the data is modelled, details on which are 
below, are in the Green box. Reproduced from (Friston et al 2006) 
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2.2.1.1 Spatial realignment 
The aim of this stage is to correct for motion artefact by adjusting the images so 
that they are always in the same position. The realignment procedure consists of 
two steps – registration and then transformation. In the registration step, 
successive image volumes are realigned to a single reference volume. This is done 
with the use of a rigid body transformation which makes the assumption that 
because the size and shape of the images to be aligned are identical, they can be 
superimposed upon each other by using a combination of three translations 
(moving the whole image volume along x, y and z axis) and three rotations (rotating 
the image volume through the x, y and z axis) (Huettel et al 2009). In the 
transformation/interpolation step the data is re-sampled in order to estimate the 
values that would have been present had no head motion taken place. After 
realignment, which deals with any linear shifts, there are still significant levels of 
variance resulting from subject movement within the scanner therefore another 
step is required – unwarping. The images acquired in the scanner are distorted due 
to inhomogeneities in the magnetic field, these also change as the subject moves 
and with the use of the subject movement parameters from realignment, the field 
maps which assess distortion of the reference image, and estimations of changes in 
the magnetic field due to subject movements via iteration then an estimate of 
distortion at each time point can be given which can be used for unwarping of the 
data. Following this, the functional-structural coregistration step takes place in 
which the functional and structural images are aligned with each other in order to 
allow for the overlay of functional activations on to individuals’ own anatomy.   
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2.2.1.2 Spatial normalisation 
In this stage the images are warped so they fit the standard template brain. 
Different subjects will have different brain volumes and shapes and therefore in 
order to make statistical inferences over groups it is essential that the images can 
be compared with each other. Normalisation attempts to compensate for these 
differences in shapes by warping the images so they are the same as those of other 
brains.  I used the unified segmentation algorithm available in SPM to perform 
normalisation. 
2.2.1.3 Spatial smoothing 
In this step the data is filtered with a Gaussian filter. Gaussian filters have the shape 
of a normal distribution (or bell-curve). The reason for the introduction of this filter 
is to spread the intensity of each voxel over nearby voxels. As fMRI data has spatial 
correlations due to functional similarities between adjacent brain areas and 
blurring due to vasculature, by smoothing data, activation is distributed over a 
range of voxels. Due to the fact that subjects are unlikely to have activations in 
exactly the same voxels as each other when the data is combined, the activation is 
spread over adjacent voxels and by introducing a Gaussian filter the signal to noise 
ratio is increased. Another advantage of smoothing is that it improves the validity of 
statistical techniques by increasing the normality of data because averaging over 
multiple observations tends towards the normal distribution and parametric 
statistical tests assume that error is normally distributed.   
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2.2.2 General linear model (GLM) 
The general liner model is used to construct the design matrix which is a 
mathematical representation of the experiment. The core concept of this 
regression model is that the value of the observed data (y) can be explained by a 
linear combination of a set of regressors  (xi) each with a variable weighting (βi) and 
residual noise in the data (error – ε). The letter β represents how much each 
regression factor contributes to the overall data. β0 is the term for all the factors 
held constant throughout the experiment. The basic formula for the regression 
analysis is as follows: 
y  = β0  +  β1x1  +  β2x2 + … +  βnxn  +  ε 
In the general linear model the statistical significance of a regressor is assessed by 
the amount of variability it explains compared with the amount of variability 
explained by the error term.  
2.2.2.1 Parameter estimation using GLM 
The design matrix is constructed by the experimenter based on the hypothesised 
effects of experimental manipulations whereas the parameter weights and residual 
error are calculated during the analysis (figure II.IV).  
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Figure II.IV: fMRI data (y) is a two dimensional data matrix consisting of n time 
points by V voxels (the spatial structure is not used in the GLM they are arranged 
along one dimension for ease of calculation). The design matrix consisting of M 
regressors each n time points in length. The parameter matrix contains M 
parameter weights and V voxels such that each cell indicates the β value for a given 
voxel. The error matrix expresses the residual error for each voxel so is a n by V 
matrix. Reproduced from Huettel  (Huettel et al 2009) 
 
The best fitting mode is then found classically using the sum of least squares 
method, although other methods are also available such as variational Bayes.  
fMRI provides information about changes in activations over time and hypotheses 
require comparison of activations between conditions. In order to find the 
variability explained by a regressor of interest, contrasts are run on the matrix. In 
order to test an experimental hypothesis it is necessary to test whether the 
experimental manipulation has caused a significant shift in the parameter weights 
(on how much each regressor contributes to the overall data). T-contrasts assume a 
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directional hypothesis and are uni-dimensional (vectors) whereas F-contrasts are 
non-directional and multi-dimensional (matrices).  There are several types of T-
contrasts which can be run to establish this. The first and simplest contrast is one in 
which the effect of one regressor causes a difference in fMRI BOLD signal. This can 
identify voxels in which activation is increased compared with the other regressors 
(by assigning a weight of +1 to the regressor of interest and 0 to the other 
regressors) or decreased compared with other regressors (by assigning a weight of  
-1 to the regressor of interest and 0 to the other regressors). In the second type, 
two conditions are directly contrasted by giving one regressor the contrast weight 
of +1 and the other of -1. This uses subtractive logic which compares 2 variables 
which are assumed only to differ in one property- the independent variable. 
Another option is to test a non-directional hypothesis by comparing a set of 
contrasts with an F-test. As well as being non-directional the F-contrast can test 
whether any combination of contrasts can explain the variablility in the data but 
does not indicate which of the contrasts are driving significance, just that there is 
significant difference between the conditions.   
2.2.3 Haemodynamic response function (HRF) 
To create design matrices the haemodynamic response is convolved with predicted 
neural activity. There are several types of haemodynamic response functions 
available in different statistical packages. In the experiments described the 
heamodynamic response is convolved with the canonical HRF which is a mixture of 
gamma functions (Friston et al 2006).  
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It is also possible to include additional regressors in the design matrix to model 
additional small differences in haemodynamic onset or the shape of the 
haemodynamic response. This is possible with the use of temporal or dispersion 
derivatives which improve robustness of a model to small variations in the timing of 
the haemodynamic response or in the width of the haemodynamic response 
respectively (Friston et al 2006), these have not been used in the experiments in 
this thesis. 
2.2.4 Event related design 
There are two main experimental designs. The blocked design, in which 
experimental conditions are separated into distinct blocks which are presented for 
an extended period of time, and event-related design, consisting of short duration 
events often with randomised timing and order (Huettel et al 2009). The 
experiments in this thesis used an event related design. In event related design the 
fMRI data is time-locked to stimulus presentation and then averaged over all trials. 
The main advantage of this type of trial is that it provides better information on the 
shape and timing of the haemodynamic response.  Other benefits include 
increasing the ability to randomise the trials so performance is not systematically 
influenced by performance on previous trials (Josephs & Henson 1999). It also 
reduces predictability present in blocked design allowing for the studying of aspects 
such as novelty and priming.  
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2.2.5 Inferences about subjects versus populations: Random vs Fixed effects 
analysis 
 
Fixed effect analysis allows for inferences about the group of subjects who took 
part in the study but in order to make inferences about populations one needs to 
use a random effects analysis. In a fixed effects analysis, the assumption is made 
that the experimental effect is constant across subjects and that any inter-subject 
variability is due to the influence of random noise. Therefore, in this type of analysis 
the error term conflates within and between-subject variance. The major 
disadvantage with this type of analysis is that it is very sensitive to extreme results 
even if they are present in only a few subjects within the sample.   
In order to make inferences about a population, subjects need to be treated as 
random variables. The most widely used method for fMRI analysis is to use mixed 
models whereby experimental factors are fixed but the subject factor is random. In 
SPM this is achieved by a two stage process. In the initial stage, contrasts of 
parameters are estimated from a fixed effects model for each subject and then 
images of these contrasts become the data for a second design matrix.  
2.2.6 Problem of multiple comparisons 
This problem arises from the fact that when large amounts of data are collected, as 
is the case in an fMRI experiment, one must perform multiple statistical tests. 
However the more statistical tests are performed the more likely the probability of 
a false positive result. There are several methods to address the problem of 
multiple comparisons. One of the most stringent, involves controlling for the family 
wise error rate (FWE) by using the Bonferroni correction. The Bonferroni correction 
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states that in order to correct for multiple statistical tests, the significance level of 
each individual test needs to be equal to the overall significance level aimed for 
(usually less than 0.05) divided by the total amount of statistical tests undertaken. 
So in fMRI data this would involve dividing the target alpha value by the total 
number of voxels being tested.  
αbon = α/V 
where V=number of voxels and α = desired significance level for the whole family of 
tests. 
However this correction is very stringent and although it reduces the chance of a 
Type I errors (false positives) it also greatly increases the chance of a Type II errors 
(false negatives). Furthermore, the Bonferroni correction assumes independent 
voxels but due to the fact that fMRI data is spatially correlated, and becomes even 
more spatially correlated after spatial smoothing, the Bonferroni correction is too 
conservative for brain images (Sarty 2007). 
An alternative approach is called the false discovery rate (FDR) and this describes 
the probability of having at least one false positive result given the set of reported 
positive results. This method of correction uses the amount of suprathreshold 
voxels and controls the expected proportion of false positives within this group. 
This method is dependant on the distribution of p-values and is therefore 
dependant on the amount of significant activations observed in the data. This 
method is less stringent than the FWE correction. However, if the null hypothesis is 
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in fact true and there are no activations, this method will be just as stringent as 
other methods (Friston et al 2006).  
Another way to approach the problem of multiple corrections is to do what is called 
a small volume correction. By defining a specific anatomical region of the brain the 
analysis will be restricted to many less voxels then for the whole brain analyses 
which will in turn lead to a much less severe correction factor. This type of 
correction should only be implemented based on strong a-priori hypotheses .  
A further method uses thresholding based on activation clusters. Instead of 
assigning a p-value to each voxel, clusters of voxels are created on the basis of 
some initial threshold and then each cluster is assigned a p-value (Smith 2004) thus 
reducing the amount of statistical tests necessary and increasing the signal to noise 
ratio within the unit (Heller et al 2006). Part of the reasoning behind this method is 
that the likelihood of false positive decreases with increasing cluster size due to a 
reduction in the cumulative probability of two adjacent voxels being activated by 
chance. The main problem with this system is that it might ignore small but 
important activations and it also assumes that activation areas are spherical which 
is not always the case. Perhaps the most important difficulty with this method is 
that it assumes that adjacent voxels are entirely uncorrelated however due to 
spatial correlation in fMRI data, significant voxels tend to cluster together even if 
they result form noise processes (Jezzard et al 2003).  
Finally a widely used method for reducing the number of independent statistical 
tests is to use a region of interest analysis. Regions of interest can be defined either 
anatomically or on the basis of previously reported lesion or functional imaging 
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studies. Regions may also be defined using a main effects contrast from which a 
region is identified and then subsequent orthogonal interaction contrasts can be 
tested within the region (Faro & Mohamed 2010).   
When correcting for multiple comparisons an important problem arises due to the 
significance values often being correlated across adjacent voxels. Many noise 
sources such as head motion will change intensity of voxels within a brain region in 
a systematic fashion. Preprocessing steps correcting for motion and smoothing 
contribute further to this spatial correlation between activated voxels. Due to the 
interdependence between adjacent voxels, when corrections are made based on 
the total number of voxels the number of independent spatial units is greatly 
overestimated and the alpha value is too conservative. Therefore random field 
theory is required which estimates the number of statistical tests needed based on 
the spatial correlation/smoothness of the data. Random field theory utilises the 
Euler characteristic (EC), which in fMRI data is the number of blobs in an image 
after thresholding  has takern place. In order to calculate the EC at different 
thresholds is is necessary to know the amount of resolution elements or resels in an 
image which can be calculated with the help of the full-width half-maximum 
Gaussian kernel (FWHM) which is applied to the imaging data during smoothing. 
The EC, which can also be applied to 3D fMRI data, allows the experimenter to 
select the thresholding level which will yield only blobs which have a less then 0.05 
chance of having occurred by chance (Frackowiak et al 2003). By using this theory, 
the threshold for significance will be much less then the one from the Bonferroni 
73 
 
correction leading to fewer Type II errors (false negatives) with only minimal 
additional risk of additional false positives (Huettel et al 2009). 
2.2.7 Computational modelling in fMRI 
Over recent years, fMRI analysis has moved from simply measuring the brain 
responses to factors manipulated in the experimental design to experimenters 
trying to explain the data in terms of optimisation of brain responses by making 
simplifying assumptions of how the brain works with the use of mathematical 
models (Friston & Dolan 2010; Sommer & Wichert 2003).  The central idea behind 
computational modelling is that there first needs to be a model which describes a 
mapping between a set of stimulus inputs and a set of behavioural responses. The 
parameters of this model, the internal operations, are then correlated with the 
neuroimaging data (O'Doherty et al 2007). 
The approach consists of firstly fitting the computational model to subjects’ actual 
behaviour in order to find specific values for the parameters in the model which 
minimize the difference between the model predictions and the behavioural data. 
Once the best fitting model parameters have been found, they can be regressed 
against the fMRI data and convolved with the haemodynamic response function. 
(O'Doherty et al 2007).  
In the experiment described in Chapters 3 and 4 a simple prediction error based 
reinforcement-learning (RL) model (Sutton 1998) was used to predict a trial-by-trial 
measure of  stimulus value (see below), and thus an outcome prediction error δ, 
which was defined as the difference between the actual observed outcome R 
(correct/incorrect = 1/0) and the current expected value of the chosen stimulus.  
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For each pair of stimuli A and B, the model estimated the expected values of 
choosing A, (QA) and choosing B (QB), on the basis of the individual sequences of 
choices and outcomes. The expected values were set to zero before learning.  After 
every trial t>0 the value of the chosen stimulus (say A) was updated according to 
the rule QA(t+1) = QA(t) + α*δ(t). The outcome prediction error is defined as the 
difference between the actual and expected outcome, δ(t)=R(t) – QA(t) with the 
actual outcome being either ‘Correct’ or ‘Incorrect’ (1 or 0).   
Given the expected values, the probability (or likelihood) of the observed choice 
was estimated using  the softmax rule : 
PA(t)=exp[QA(t)/β]/{exp[QA(t)/β]+exp[QB(t)/β]}. The parameters α (learning rate) 
and β (temperature) were adjusted to maximise the likelihood of the actual choices 
under the model, for all subjects.  
The outcome prediction errors which had been estimated by the model on a trial-
by-trial basis were then used as parametric regressors in the imaging data. 
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2.3  Drug experiments  
Two of the experiments described in this thesis involve a drug manipulation. In the 
experiment described in chapters 3 and 4 ‘Dopamine and performance in a 
reinforcement learning task – evidence from Parkinson’s disease’, a crossover 
design was employed and in the experiment described in chapter 6 ‘Expectations 
and violations: Probing the role of dopamine in set shifting’ a double-blinded 
crossover design was employed.   
2.3.1 Crossover design used in: “Dopamine and performance in a reinforcement 
learning task – evidence from Parkinson’s disease” 
In a three period crossover design subjects are randomised to one of six sequences 
(in our study OFF-OFF then OFF-ON then ON-ON medication, OFF-OFF then ON-ON 
then ON-OFF medication, OFF-ON then OFF-OFF then ON-ON medication, OFF-ON 
then ON-ON then OFF-OFF medication, ON-ON then ON-OFF then OFF-OFF 
medication, ON-ON then OFF-OFF then OFF-ON medication) with each subject 
having the same probability of being selected for each sequence.  
2.3.2 Double-blinded crossover design used in: “Expectations and violations: 
Probing the role of dopamine in set shifting” 
The medication manipulation design employed in this study was that of a 
randomised double-blinded crossover trial.  In a two period crossover design, (such 
as was employed in this experiment) subjects are randomised to one of two 
sequences (placebo-then-drug or drug-then-placebo) with each subject having the 
same probability of being selected (50%) for each sequence.  
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2.3.3 Advantages and disadvantages of crossover designs 
 
The main advantage of a crossover design is that each subject serves as their own 
control and as such sample sizes can be smaller (Gallin & Ognibene 2007). It also is 
a very useful method to employ when the group being studied is a heterogeneous 
patient group such as Parkinson’s disease patients as it can significantly reduce the 
sample size needed to test. The main disadvantage in a crossover design is the 
potential for either drug or performance carryover effects. In order to try to 
minimise these carryover effects the sessions were scheduled a minimum of one 
week apart, the aim of which was firstly to attempt to minimise as much as possible 
any potential effect of the preceding drug manipulation on performance in 
subsequent sessions, by allowing for complete drug washout and also to allow the 
subjects to forget as much as possible their previous performance. In addition, all 
the symbols were changed between sessions to minimise learning carryover 
between the sessions. Finally,  the the order of the crossover was randomised to  
minimise the order effect.   
In the final experiment in the thesis (chapter 6) both the subject and the 
investigator were ‘blinded’ to the sequence order which has the effect of reducing 
investigator and subject bias (Gallin & Ognibene 2007). 
  
77 
 
Chapter 3  
Dopamine and performance in a 
reinforcement learning task – 
evidence from Parkinson’s 
disease  
 
Behavioural results 
In the experiment described in this chapter I used the model afforded by PD to 
tease apart the influence of dopamine on learning from its influence on action 
performance. I sought to dissociate dopaminergic effects on learning from effects 
on choice and to test whether reinforcement learning impairments in Parkinson's 
disease (PD) are related to the acquisition or to the performance component of 
reinforcement learning. In this chapter I will describe the behavioural procedure 
and behavioural results and in Chapter 4 I will details the fMRI procedure and the 
imaging results. 
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3.1 Introduction 
Dopamine is strongly implicated in reward signalling, and plays a central role in 
reward learning in animals (Bayer & Glimcher 2005; Schultz 1998; Schultz et al 
1997; Wise 2004; Wise & Rompre 1989)  and humans (Pessiglione et al 2006). 
Accumulating evidence from pharmacological interventions in healthy subjects 
(Pessiglione et al 2006) and patients with Parkinson’s disease studied ON and OFF 
medication (Frank et al 2007; Frank et al 2004) indicates that manipulating 
dopamine transmission in humans influences reward-related reinforcement 
learning and decision-making. A common assumption arising from these data is that 
dopamine exerts a direct effect on instrumental learning, a form of learning that 
links actions and their outcomes. Indeed, at a mechanistic level, activity in 
dopaminergic neurons  is known to express a prediction error believed to mediate 
learning and updating the reward value of predictive stimuli (Schultz et al 1997). 
The idea that prediction error based learning is computationally implemented via 
activity patterns within the dopaminergic system is supported by a substantial body 
of experimental work across species (see (Haber & Knutson 2010) for review). 
 
However, dopamine does not solely impact on reinforcement learning. Evidence 
now points to a much broader range of influences including a contribution to the 
control of Pavlovian approach behaviour (Dreher et al 2007; Ikemoto & Panksepp 
1999; Parkinson et al 2002) as well as in motivational engagement and vigour 
(Bardgett et al 2009; Berridge & Robinson 1998; Boureau & Dayan 2011; Lex & 
Hauber 2010; McClure et al 2003b; Niv 2007; Niv et al 2007). These influences on 
behaviour are distinct from learning (Yin et al 2008), even in  cases where  they 
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arise from a signal that actually reports a prediction error (McClure et al 2003b). 
We note here that previous studies investigating the effect of dopamine typically 
cannot distinguish between action learning and action performance (Cools et al 
2001a; Frank et al 2007; Frank et al 2004; Pessiglione et al 2006). Consequently, it 
remains possible that the reported dopamine-dependent impact arises not from an 
influence on learning as such, but rather from a modulation of the expression of 
learning, i.e. an effect on actual choice behaviour or performance. 
 
Parkinson’s disease (PD), is a common neurological disorder characterised by 
neuronal loss in the substantia nigra (SN)(Edwards 2008) that leads to depleted 
levels of striatal dopamine (Koller 2007). PD results in deficits across several 
cognitive domains, including probabilistic learning and classification tasks (Graef et 
al 2010; Knowlton et al 1996), with dopamine replacement therapy (DRT) having 
distinct effects on these behaviours. For example, when PD patients are OFF DRT, 
their expression of learning from positive feedback is impaired (Frank et al 2007; 
Frank et al 2004) and when ON  DRT they show  impaired performance in learning 
from negative outcomes (Frank et al 2004; Rutledge et al 2009). This behavioural 
pattern has been attributed to increased levels of striatal dopamine when patients 
were ON their DRT boosting prediction error signals resulting in enhanced learning 
from positive outcomes. By contrast, a prevention of dips in dopaminergic activity, 
as observed with omission of expected outcomes, has been suggested to worsen 
learning from negative outcomes (Frank et al 2007; Frank et al 2004; Maia & Frank 
2011).  
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Here, I sought to dissociate dopaminergic effects on learning from effects on choice 
by performing neuroimaging during a reinforcement learning task with patients 
suffering from Parkinson’s disease (PD). I employed a two stage learning task which 
involves separate phases of (a) acquisition and (b) a subsequent performance 
testing involving generalisation. This task has provided an effective means of 
examining the neural mechanisms underlying cognitive deficits in PD (Frank et al 
2007; Frank et al 2004). These previous studies focused on learning, while here we 
probed the effect of dopaminergic status (ON medication, and OFF medication) 
both on learning action contingencies and on performance during behavioural 
extinction. Crucially, this dissociation between learning and performance has not 
been explicitly explored in previous human investigations. An influence of 
medication on the acquisition phase would provide support for an effect of 
dopamine on learning while an effect confined to performance would support the 
alternative hypothesis, namely that the influence of dopamine includes other 
processes, such as Pavlovian approach or performance motivation. 
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3.2 Materials and methods 
The study and its procedures were approved by the National Research Ethics 
Service, The Joint UCL/UCLH Committees on the Ethics of Human Research 
(Committee A). 
3.2.1 Participants  
Fourteen early- to moderate-stage [H+Y stage- mean (SE) 1.69 (0.26)] idiopathic 
Parkinson’s disease patients (ten males) (as per UK Brain bank criteria) aged 
between 44 and 81 years [mean (SE) 61.8 (3.3) years] participated in and completed 
the study. Patients were recruited from the movement disorder clinic at the 
National Hospital for Neurology and Neurosurgery (NHNN).   
 
We obtained written informed consent from all subjects and transport costs were 
reimbursed. 
 
Subjects were interviewed for psychiatric and neurological history as well as current 
and past medication. They were also examined by a clinician and asked to complete 
several questionnaires including a health questionnaire, a mini-mental state 
examination and an impulse control disorder screening questionnaire (Appendix; 
table 3.5.1). 
One subject had difficulty understanding the task demands, and adopted an 
incorrect strategy for stimulus selection whereby he explicitly believed the incorrect 
stimulus to be correct and continued to select it despite ongoing negative feedback 
resulting in significantly worse than chance performance. Data from this subject are 
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not included in any analyses. Another subject was excluded from the imaging 
analysis due to an incidental finding of abnormally large ventricles, preventing 
successful normalisation of this dataset to a standard coordinate space. Hence, 13 
subjects were analysed behaviourally and 12 subjects were analysed in the fMRI 
study. 
 
Twelve of the subjects were right-handed and one was left handed. All were fluent 
English speakers. The duration of Parkinson’s disease varied from 1 to 10 years 
from the time of initial diagnosis [mean (SE) 4.9 (0.96) years]. Subjects had no 
history of other major neurological or psychiatric disease. Patients were all on 
levodopa/carbidopa combinations; eight patients were also on dopamine agonists; 
total daily dose of levodopa/carbidopa varied from 50/12.5mg to 1000/255 mg 
[mean (SE) 400/100 (74.4/18.6) mg] (Appendix: table 3.5.2). We did not recruit 
patients on trihexyphenidyl, benzhexol or high dose tolterodine due to possible 
confounding effects of high dose anti-cholinergic medication, or patients on 
amantadine due to its effect on multiple neuromodulators.  
3.2.2 Stimuli 
We used a version of the generalization task introduced by Frank et al (Frank et al 
2007; Frank et al 2004).  Stimuli consisted of Hiragana symbols which were 
presented in white fonts on a black background. Each stimulus had a different 
probability of being correct when selected. These probabilities ranged from 80% to 
20%. In the first, or acquisition, stage of the task, the symbols were paired to form 3 
sets: the 80% stimulus was paired with the 20% stimulus, the 70% stimulus was 
paired with the 30% stimulus and the 60% stimulus with the 40% stimulus. The sets 
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were presented in a randomized order. In the second, or performance, phase, along 
with all the training pairings, the best stimulus (the one with 80% chance of being 
correct) and the worst stimulus (the one with only 20% chance of being correct) 
were presented in novel pairings with all the other stimuli (see figure III.I for task 
depiction). 
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Figure III.I: Task. Stimuli consisted of Hiragana symbols which were presented in 
white fonts on a black background. Each stimulus had a different probability of 
being correct when selected. In the first, or acquisition, stage of the task, symbols 
were paired to form 3 ‘training pairs’ which remained the same throughout this 
phase: the 80% stimulus was paired with the 20% stimulus, the 70% stimulus was 
paired with the 30% stimulus and the 60% stimulus with the 40% stimulus. Subjects 
selected the left or right stimulus by button presses and, during the acquisition 
phase, also received information about the outcome (correct/incorrect). In the 
second, or performance, phase, along with all the training pairings, the best 
stimulus (the one with 80% chance of being correct) and the worst stimulus (the one 
with only 20% chance of being correct) were presented in novel pairings with all the 
other stimuli. During this phase subjects did not receive information about the 
outcome of their choice.  
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3.2.3 Procedure 
Overview 
Each patient participated in three separate sessions on different days, which were a 
minimum of one week apart (i.e. a within subject design). Each session involved 
different Hiragana symbols (see figure III.I for details). All patients performed the 
task in three different drug states (see table 3.1 for details): acquisition and 
performance in the ON state (ON-ON), acquisition and performance in the OFF 
state (OFF-OFF), and acquisition of the stimulus contingencies in the OFF state but 
performance in the ON medication state (OFF-ON). The order of the different drug 
states in which patients performed the task was randomised. The OFF state in two 
of the conditions was achieved by a minimum of 12 h withdrawal from all 
dopaminergic medication and omission of all slow release preparations for a 
minimum of 18 h. On the remaining day (ON-ON), patients were asked to take their 
morning dopaminergic medication as usual. We were unable to test patients in the 
ON-OFF state, i.e. acquisition in the ON state and performance in the OFF state, due 
to the half life of levodopa/carbidopa combinations which would require a 
minimum of 7.5 hours to be metabolised and excreted resulting in too long an 
interval between the acquisition and performance phases.  All patients were tested 
at similar times in the morning to equalize washout times and to control for diurnal 
symptom fluctuations.  
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 Phase 1: Acquisition Break Phase 2: Performance 
State 1 OFF 50 mins OFF 
State 2 ON 50 mins ON 
State 3 OFF 50 mins ON 
 
Table 3.1: Drug states in which the task was carried out 
Each patient returned three times to perform the task. In ‘state 1’ the subjects 
undertook both the first and second phases of the task in an OFF medication state. 
In ‘state 2’ subjects undertook both the first and second phases of the task in an ON 
medication state. In ‘state 3’ subjects undertook the first phase, the acquisition 
phase, in an OFF medication state. Following completion of the first phase, patients 
then received their dopaminergic medication and undertook the second phase of the 
task, the performance phase, in an ON medication state.  The order of the states 
was randomised across subjects. On all three days there was a break of 50 minutes 
between the first and second phases of the task to allow for dopaminergic 
medication to be given after the first phase in ‘state 3’ and to allow for adequate 
absorption time but to ensure consistency across all 3 days.  
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To familiarise subjects with the structure of the task we undertook a short practice 
block before the first scanning session. During that practice session, patients 
worked on an identical task as in the main study except for the fact they were 
presented with different Hiragana symbols. The main session began with two 
functional scans (scans 1 and 2, acquisition sessions). Most subjects completed a 
third acquisition session on a laptop. In OFF-ON condition patients took their 
medication following this training. All patients then waited for 45-60mins before 
undergoing a third functional scanning session (scan 3, performance session) for 
performance testing.    
On one of the three days, after the training and performance stages were complete, 
the patients also underwent a structural scan, a mini-mental state examination and 
completed questionnaires as detailed above.  
 
Acquisition phase of the task (scanning bouts 1 and 2) 
Scanning bouts 1 and 2 (acquisition phase of the task), lasted approximately 16 min, 
and consisted of 120 trials of 8 s each. On each trial, two Hiragana characters 
appeared on the screen side by side, presented via a mirror mounted on the head 
coil. Subjects’ task was to select one of the characters on each trial by pressing 
either the right or the left key on a button box. The stimuli remained on the screen 
for 4 s, followed by presentation of the outcome (either ‘Correct’ or ‘Incorrect’) for 
2 s. The likelihood of being correct or incorrect was probabilistically determined for 
each stimulus (see above).  If subjects did not respond within the 4 s that the 
stimuli were on the screen the message ‘no key pressed’ was presented and the 
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trial was excluded from the analysis. A fixation cross was presented for 2 s during 
the inter-trial interval (ITI). 
 
Performance phase of the task (scanning bout 3) 
Scanning bout 3 (performance phase) was 10 min long and consisted of 110 trials of 
6 s each. Similar to the acquisition phase, two Hiragana characters were presented 
side by side on each trial and subjects had to select one of the characters by 
pressing either the right or the left key. As before, characters remained on screen 
for 4 s. This time subjects did not receive feedback after making a response and the 
trial instead progressed immediately to the presentation of a fixation cross during 
the 2 s ITI. 
Importantly, in addition the stimulus pairs used during training (80% with 20%, 70% 
with 30%, and 60% with 40%), the symbols were shown in eight novel pairings. Four 
of the pairings had the ‘best’ stimulus paired with all other stimuli (80% with 70%, 
80% with 60%, 80% with 40% and 80% with 30%), and the other four pairings 
compared the ‘worst’ stimulus to all other stimuli (20% with 70%, 20% with 60%, 
20% with 40% and 20% with 30%). All pairs were presented 10 times each in 
randomized order, resulting in 110 pairs overall (see figure III.I task depiction). 
3.2.4 Data Analysis  
Acquisition sessions 1, 2 and 3 
All subjects reached at least 65% accuracy in the easiest pairing or after completion 
of 3 acquisition sessions had a minimum accuracy of 60% over all training pairs 
before proceeding to the performance phase. Accuracy levels in the acquisition 
phase were then separately computed for each drug state by averaging the overall 
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accuracy across all acquisition sessions on that day. The measure used was percent 
of trials on which the correct stimulus, i.e. the stimulus with the highest 
probabilistic contingency in each training pair, was selected. We then compared 
overall accuracy during acquisition in the ON condition to overall accuracy in the 
two OFF medication states using paired t-tests and a linear mixed model to detect 
differences in accuracy in the acquisition phase between different drug states.  We 
also tested for differences in the acquisition rate between the different drug states 
by comparing learning rates in a reinforcement learning (RL) model (see below). For 
this test we individually fitted the parameters of the RL model to subjects’ choices 
in the ON and OFF medication condition, comparing the resulting learning rates 
using a paired t-test. 
 
Performance session 
Data from the performance session were separated into trials in which the ‘best’ 
stimulus (80% chance of being correct) was presented, and trials in which the 
‘worst’ stimulus (20% chance of being correct) was presented. We calculated the 
percentage of times subjects picked the best stimulus and the percentage of times 
the subjects avoided the worst stimulus in these novel pairings and tested for any 
differences in performance between the different medication conditions.  
 
Reinforcement Learning Model 
We used a simple prediction error based reinforcement-learning (RL) model (Sutton 
1998) to predict a trial-by-trial measure of  stimulus value, and thus an outcome 
prediction error δdefined as the difference between the actual observed outcome R 
(correct/incorrect = 1/0) and the current expected value of the chosen stimulus.  
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For each pair of stimuli A and B, the model estimates the expected values of 
choosing A, (QA) and choosing B (QB), on the basis of individual sequences of 
choices and outcomes. The expected values were set to zero before learning.  After 
every trial t>0 the value of the chosen stimulus (say A) was updated according to 
the rule QA(t+1) = QA(t) + α*δ(t). The outcome prediction error is the difference 
between the actual and expected outcome, δ(t)=R(t) – QA(t) with the actual 
outcome being either ‘Correct’ or ‘Incorrect’ (1 or 0).  Values of stimuli that were 
not shown on a trial were not updated. 
Given the expected values, the probability (or likelihood) of the observed choice 
was estimated using  the softmax rule : 
PA(t)=exp[QA(t)/β]/{exp[QA(t)/β]+exp[QB(t)/β]}. The parameters α (learning rate) 
and β (temperature) were adjusted to maximise the likelihood of the actual choices 
under the model, for all subjects. Trial-by-trial outcome prediction errors estimated 
by the model were then used as parametric regressors in the imaging data. 
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3.3 Results 
We employed a within subject design given the inherent difficulty in accurately 
matching PD patients with different disease severity, we also believe that this 
design allowed us to minimise as far as is possible individual cognitive and genetic 
differences that may exist in our cohort, allowing us to look at the within subject 
effects of drug on behaviour. In parallel with our behavioural analysis, we also 
acquired neural data using fMRI. The fMRI results will be discussed in the next 
chapter (chapter 4). Thus, our design enabled us to explore the effect of dopamine 
on behaviour and on the brain by testing patients in three different drug states;  
acquisition and performance ON medication, acquisition and performance OFF 
medication and acquisition in an OFF medication state and performance in an ON 
medication state. This inclusion of the latter condition specifically enabled us to 
probe whether dopamine affected the acquisition or performance aspects of the 
task. 
Acquisition phase results 
At the end of the acquisition phase, average choice accuracy on the training pairs 
did not differ between groups in different drug states (paired t-tests comparing ON-
ON with OFF-ON; T (1,12) =0.15, p=0.87, comparing ON-ON with OFF-OFF; T (1,12) 
=0.095  p=0.92, comparing OFF-ON; with OFF-OFF T(1,12)= -.079p=0.93) (table 3.2).   
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Subject ON_ON OFF_ON OFF_OFF 
1 77% 85% 71% 
2 71% 87% 87% 
3 70% 71% 65% 
4 70% 62% 82% 
5 97% 100% 92% 
6 80% 79% 86% 
7 63% 53% 84% 
8 56% 62% 68% 
9 94% 53% 65% 
10 67% 62% 64% 
11 34% 70% 65% 
12 92% 63% 59% 
13 75% 89% 54% 
 
Table 3.2: Choice accuracy  
Average choice accuracy on the training pairs after the final training session in each 
of the medication groups. All subjects reached at least 65% accuracy in the easiest 
pairing or after completion of 3 acquisition sessions had a minimum accuracy of 
60%. 
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Similarly, we found no significant difference in learning rates between patients 
when they were in an OFF compared to ON medication state (mean (SE) ON 0.25 
(0.02) and OFF 0.24 (0.01), paired t-test T (1,12) =0.117, p=0.90) ( figure III.II, table 
3.3), or in the number of sessions required to reach criteria (mean (SE) ON 1.23 
(0.12) OFF 1.38 (0.16) paired t-test T (1,12) =-0.69, p=0.50). There were also no 
differences between positive and negative learning rates.  
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Subject ON OFF 
1 0.175 0.3221 
2 0.2324 0.2351 
3 0.2267 0.2012 
4 0.2797 0.3064 
5 0.1486 0.1779 
6 0.3678 0.1712 
7 0.3443 0.2851 
8 0.2004 0.2348 
9 0.1935 0.219 
10 0.473 0.3216 
11 0.2527 0.2078 
12 0.1828 0.2062 
13 0.175 0.3221 
 
Figure III.II and table 3.3: Learning rates 
Learning rates were fitted separately per subject in the different drug conditions. All 
bouts were considered equally during fitting. The data in the ‘ON’ group came from 
the 3 bouts they performed in the ON medication state; the data in the ‘OFF’ group 
came from the 6 bouts they performed in the OFF medication state. 
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Performance phase results:  
In the performance phase, along with all the training pairings, we presented the 
best (the one with 80% chance of being correct) and worst stimulus (the one with 
only 20% chance of being correct) in novel pairings with all the other stimuli (see 
above for task depiction). We found that patients ON their DRT performed 
significantly better than patients OFF their DRT (main effect comparing accuracy of 
the mean of ON-ON/OFF-ON with OFF-OFF, paired t-test, T (1,12) =2.8, p=0.01). 
Crucially, a separate examination of the three drug states revealed a main effect of 
drug on performance but not on acquisition (figure III.III). Subjects who acquired 
the contingencies in an OFF medication state and received their DRT after the 
acquisition phase, but before the performance phase, had the same level of overall 
accuracy as subjects who both acquired the contingencies ON medication and 
performed ON medication (paired t-test comparing ON-ON with OFF-ON, T=-0.03, 
p=0.97). Both the ON-ON and OFF-ON groups were significantly more accurate then 
the OFF-OFF group (paired t-test comparing ON-ON with OFF-OFF, T=2.17 p=0.05; 
and comparing OFF-ON with OFF-OFF, T (1,12) =2.28 p=0.04).  A mixed effects linear 
model showed a significant effect of drug state on the performance phase 
(F(1,36)=5.38 p=0.02) but not on the acquisition phase (F(1,36)=0.002 p= 0.96).   
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Figure III.III: Accuracy during performance phase in novel pairings. Accuracy was 
significantly higher when subjects were ON DRT during the performance phase than 
when they were OFF (p=0.01). This effect is independent of drug state during the 
previous acquisition phase. Shown is the combined accuracy in selecting the best 
stimulus and avoiding the worst stimulus over the 3 drug states when subjects had 
to pick the stimulus with the highest likelihood of being correct when presented in 
novel parings. ON-ON session (blue) –when patients took their usual DRT, OFF-ON 
session (blue/red striped) when patients took their DRT only after completing the 
acquisition phase, OFF-OFF session (red) when patients abstained from their DRT 
throughout the task. The error bars represent s.e.m. 
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In addition to the novel pairings, subjects were also presented with the three 
stimulus pairs on which they had been trained during acquisition. Interestingly, we 
found no differences in accuracy levels on these training pairs across the different 
drug states (paired t-tests comparing ON-ON with OFF-ON T (1,12) =-1.36, p=0.19, 
comparing ON-ON with OFF-OFF T(1,12) = -0.64 p=0.52, comparing OFF-ON with OFF-
OFF T(1,12) = 1.26 p=0.23) (figure III.IV). There were no differences in the training pair 
compared with novel pair accuracy in ON-ON or OFF-ON drug states (paired t-tests 
comparing training pair accuracy with novel pair accuracy in ON-ON T(1,12) = -.93, 
p=0.36; and OFF-ON drug states T(1,12) =-.99, p=0.33), but as expected, there was a 
significant difference between training pair compared with novel pair accuracy in 
the OFF-OFF drug state (T(1,12) =-3.65,p= 0.003).  
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Figure III.IV: Accuracy during performance phase in training pairs. Accuracy in 
selecting the better stimulus among the training pairs during the performance 
phase did not differ between drug states. Shown is the combined accuracy in 
selecting the best stimulus and avoiding the worst stimulus over the 3 drug states 
when subjects had to pick the stimulus with the highest likelihood of being correct 
when presented in the contingencies which they have previously trained on. ON-ON 
session (blue) –when patients took their usual DRT, OFF-ON session (blue/red 
striped) when patients took their DRT only after completing the acquisition phase, 
OFF-OFF session (red) when patients abstained from their DRT throughout the task.  
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The maintained performance in the training pairs also makes an extinction effect, 
whereby patients OFF medication are less sensitive to the lack of positive feedback 
and therefore perform progressively worse during the session, much less likely. This 
is due to the fact that patients OFF medication were able to maintain their 
performance on the training pairs, which were randomly interspersed with the 
novel pairs, throughout the test session. This observation also makes it unlikely that 
the performance differences between the groups are due to a selective sensitivity 
in the OFF group to the time delay between acquisition and transfer. 
 
We next tested for differential performance in selecting the best, and avoiding the 
worst, stimulus within the novel pairings. Interestingly, being in the ON DRT state 
during the performance phase selectively improved accuracy in selecting the best 
stimulus compared to avoiding the worst stimulus for novel stimuli pairs (paired t-
tests comparing ON accuracy for picking the best compared with avoiding worse 
stimulus T(1,12) =2.16, p= 0.05). This performance difference between selecting the 
best and avoiding the worst stimulus was not evident when subjects both acquired 
and performed the task in the OFF medication state (paired t-tests comparing OFF 
accuracy for picked best compared with avoiding worse stimulus T(1,12) =0.58, 
p=0.56), although their overall performance was worse (figure III.V). Of note, there 
was no interaction between the medication status (ON vs OFF) during performance 
and the ability to pick the best compared with avoiding the worst stimulus as has 
previously been reported (Frank et al 2007; Frank et al 2004).We only found this 
selective improvement in picking the best stimulus compared with avoiding the 
worst stimulus within the ON group.  
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Figure III.V: Differences in accuracy at picking best compared with avoiding worst 
stimuli. ON state during performance phase selectively improved accuracy for 
picking the best stimulus (the 80%) compared to avoiding the worst stimulus (the 
20% stimulus) in novel pairings. The data in the ‘ON’ state comes from the 2 
performance bouts performed in this medication state and the data in the ‘OFF’ 
state comes from the 1 performance bout performed in this medication state.  
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3.4 Discussion 
We show a striking effect of dopamine replacement therapy (DRT) on the ability of 
PD patients to select the highest valued stimulus in a probabilistic reinforcement 
learning task. Importantly, our data show that medication status at the acquisition 
task phase did not impact on successful task learning. Instead, the data show that 
the critical factor was medication status at the performance phase, by which time 
stimulus values had already been acquired successfully.  The findings challenge the 
proposal that the impact of dopaminergic status on this form of decision making 
solely reflects its involvement in learning. 
 
Our key observation was that patients who were OFF dopamine during the second 
task phase performed significantly worse when stimuli occurred in novel pairings. 
However, dopaminergic drug state did not impact on their ability to select the best 
stimulus when they were required to pick between pairs on which they had been 
trained in the first phase of the task. This indicates that the subjects OFF medication 
could successfully retrieve learnt contingencies but were unable to use this 
knowledge to make correct choices when they had to select between novel 
stimulus pairings. There was no difference in learning rates or accuracy during the 
acquisition phase between the different drug conditions, indicating that dopamine 
did not impact on the ability to learn stimulus values. Consequently, it would 
appear that DRT impacted upon the ability to generalize, in a context where 
subjects needed to select the best stimulus in a state characterized by novel 
pairings.  
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The fact that patients in all three drug states performed equally well when they 
were selecting the best cue for sets on which they had been previously trained 
further indicates that dopamine did not influence patients’ accuracy by a direct 
influence on learning.  Levodopa medication in PD patients has previously been 
shown to have a positive effect on generalisation of learnt information in novel 
contexts, however those observations were on a background of impaired learning 
and therefore crucially different from our current findings  (Myers et al 2003; 
Shohamy et al 2006).  Of course, many different systems are likely to be involved in 
learning, only some of which depend directly on dopamine (Beninger 1983; Daw et 
al 2005; Dickinson et al 2000; Palmiter 2008), and we cannot discount the 
possibility that a more complex learning task, such as one involving sequences of 
choices, might be necessary to fully reveal effects of dopamine on learning.  
 
Conversely, beyond its putative role in learning, dopamine is implicated in a 
number of distinct processes related to motivation, including the control of 
preparatory Pavlovian conditioned responses, and motivational vigour (Bardgett et 
al 2009; Berridge 2007; Boureau & Dayan 2011; Dickinson et al 2000; Mazzoni et al 
2007; Niv 2007; Parkinson et al 2002; Salamone et al 2003).  Importantly, these 
remain consistent with the fact that the phasic activity of dopamine neurons codes 
for an appetitive prediction error (McClure et al 2003b). However, our study has 
enabled us to disentangle these effects from a mere effect on learning in a manner 
that provides clear evidence that dopamine has a specific role in action 
performance distinct from learning. However within this task design, we are unable 
to surmise whether the effect of medication was due to the boosting of tonic or 
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phasic dopamine levels as the drug manipulation (which included the withdrawal 
and then reinstatement of both L-DOPA and dopamine agonists) is  likely to have 
had an effect on both. 
A significant finding from this  study is that when patients were ON their DRT, they 
were worse at avoiding stimuli with the poorest probabilistic contingencies than at 
choosing the stimuli with the best probabilistic outcomes.  This is in keeping with 
previous research showing a similar outcome valence performance asymmetry, 
whereby patients ON their DRT are impaired at avoiding the least rewarding stimuli 
(Frank et al 2007; Frank et al 2004). It has been postulated that this worsening in 
performance is due to ‘overdosing’ of the striatum which interferes with the dips in 
dopamine that express negative prediction errors (Frank et al 2007; Frank et al 
2004). However, in our study as in several others (de Wit et al 2011; Jocham et al 
2011), we did not find a direct effect of medication on learning and we postulate 
that the worsened performance may reflect some other mechanism, perhaps an 
impaired expression of avoidance behaviour in a high dopamine state. Of note, we 
did not find an interaction between medication state and picking the best 
compared with avoiding the worst stimulus which has been reported in some 
previous studies (Frank et al 2007; Frank et al 2004; Voon et al 2010). We found an 
overall improvement in performance when subjects were ON and an asymmetry in 
this performance accuracy between pick best compared with avoid worst trials 
within this group.  
 
By teasing apart learning and performance during a reinforcement learning task in 
Parkinson’s patients I found that dopaminergic medication impacted performance, 
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but not learning. Thus, the improved performance in patients ON medication 
cannot be attributed to an effect on learning and must reflect some other effect of 
dopamine, perhaps Pavlovian appetitive approach or motivational vigour.  
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3.5 Appendix   
Table 3.5.1: Neuropsychological data sets 
 Patients (n=13) 
Age 61.8 (3.3) 
Education (years since age 16) 4.3 (1) 
MMSE 29 (0.32) 
ICD 1.6 (0.8) 
Values represent mean (SE). BDI = Beck Depression Inventory; MMSE=Mini Mental 
State Examination; ICD = impulse control disorder questionnaire. 
Table 3.5.2: Medications 
 Patients (n=13) 
levodopa/carbidopa 13 
Stalevo (levodopa/carbidopa/entacapone) 1 
Ropinirole 5 
Pramipexole 2 
Selegiline 2 
Rasagiline 2 
Anti-hypertensives 3 
Anti-depressants (SSRI/SNRI) 1 
Gliclazide 1 
Omeprazole 1 
Ceterizine 1 
Detrusitol 1 
Voltarol 1 
Sildefinil  1 
Aspirin 1 
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Chapter 4  
Dopamine and performance in a 
reinforcement learning task – 
evidence from Parkinson’s 
disease 
 
Functional MRI results  
This chapter follows directly from findings reported in Chapter 3 in which I 
described the behavioural findings that aimed to tease apart the influence of 
dopamine on learning from its influence on action performance. In this chapter I 
will describe the fMRI procedure and results. The aim of fMRI scanning was to 
elucidate the neural mechanisms underlying the observed differences in behaviour 
allowing a better understanding of the way in which dopamine exerts its influence 
on accuracy in a reinforcement learning task.  
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4.1 Introduction 
As mentioned in the previous chapter, the roles dopamine plays in decision making 
have important theoretical, empirical and clinical implications. Here, I examined 
this issue by exploiting the dopamine lesion deficit model afforded by Parkinson’s 
disease. We studied patients in a two stage reinforcement learning task, while they 
were ON and OFF dopamine replacement medication. In this chapter I will discuss 
the fMRI procedure and findings. 
 
At a mechanistic level, activity in dopaminergic neurons  is known to express a 
prediction error believed to mediate learning and updating the reward value of 
predictive stimuli (Schultz et al 1997), And the idea that prediction error based 
learning is computationally implemented via activity patterns within the 
dopaminergic system is supported by a substantial body of experimental work 
across species (see (Haber & Knutson 2010) for review). My first aim was to test 
whether dopaminergic drug state in PD patients (ON or OFF medication) had an 
influence on the neural representation of the magnitude of the prediction error 
signal during learning.  
 
Given  that dopamine does not solely impact on reinforcement learning and has a 
role in the control of Pavlovian approach behaviour (Dreher et al 2007; Ikemoto & 
Panksepp 1999; Parkinson et al 2002) as well as in motivational engagement and 
vigour (Bardgett et al 2009; Berridge & Robinson 1998; Boureau & Dayan 2011; Lex 
& Hauber 2010; McClure et al 2003b; Niv 2007; Niv et al 2007), I aimed to identify a 
neural basis for the behaviour we observe with the aim of differentiating the effect 
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of dopamine on learning, potentially mediated via its effect on the prediction error 
signal, from its effects elsewhere.  
 
In the previous chapter I detailed behavioural findings which demonstrate that 
medication status during the acquisition phase did not impact on successful 
learning and instead, the data showed that the critical factor was medication status 
at the performance phase, by which time stimulus values had already been 
acquired successfully.  These findings challenge the proposal that the impact of 
dopaminergic status on this form of decision making solely reflects its involvement 
in learning.  
 
My first aim was to establish if, despite the lack of behavioural differences, whether 
we could identify any neural differences between the patients in different drug 
states during the acquisition phase of the task. My second aim was to identify the 
neural substrate underlying the improved behaviour in the patients who were ON 
medication during the performance phase of the task in the hope that we would 
find a neurobiological correlate for this improved behaviour.  
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4.2 Materials and methods 
4.2.1 Experimental Paradigm  
4.2.1.1 Recap of design (for further details see chapter 3) 
We used a within subject design that enabled us to study the same group of PD 
patients (early- to moderate-stage [H+Y stage- mean (SE) 1.69 (0.26)])  in a 
generalization task introduced by Frank et al (Frank et al 2007; Frank et al 2004) in 
three separate drug states (see figure IV.I for details of task design and table 3.1 for 
experimental structure). We employed a within subject design given the inherent 
difficulty in accurately matching PD patients with different disease severity. In 
parallel with our behavioural analysis, we also acquired neural data using fMRI. 
Thus, our design enabled us to explore the effect of dopamine on behaviour and on 
the brain by testing patients in three different drug states;  acquisition and 
performance ON medication, acquisition and performance OFF medication and 
acquisition in an OFF medication state and performance in an ON medication state. 
This inclusion of the latter condition specifically enabled us to probe whether 
dopamine affected the acquisition or performance aspects of the task (see chapter 
3 for more detailed methods). 
In the task, stimuli consisted of Hiragana symbols which were presented in white 
fonts on a black background. Each stimulus had a different probability of being 
correct when selected. In the first, or acquisition, stage of the task, symbols were 
paired to form 3 ‘training pairs’ which remained the same throughout this phase: 
the 80% stimulus was paired with the 20% stimulus, the 70% stimulus was paired 
with the 30% stimulus and the 60% stimulus with the 40% stimulus. Subjects 
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selected the left or right stimulus by button presses and, during the acquisition 
phase, also received information about the outcome (correct/incorrect). In the 
second, or performance, phase, along with all the training pairings, the best 
stimulus (the one with 80% chance of being correct) and the worst stimulus (the 
one with only 20% chance of being correct) were presented in novel pairings with 
all the other stimuli. During this phase subjects did not receive information about 
the outcome of their choice (figure IV.I-depiction of task). 
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Figure IV.I: Task. Stimuli consisted of Hiragana symbols which were presented in 
white fonts on a black background. Each stimulus had a different probability of 
being correct when selected. In the first, or acquisition, stage of the task, symbols 
were paired to form 3 ‘training pairs’ which remained the same throughout this 
phase: the 80% stimulus was paired with the 20% stimulus, the 70% stimulus was 
paired with the 30% stimulus and the 60% stimulus with the 40% stimulus. Subjects 
selected the left or right stimulus by button presses and, during the acquisition 
phase, also received information about the outcome (correct/incorrect). In the 
second, or performance, phase, along with all the training pairings, the best 
stimulus (the one with 80% chance of being correct) and the worst stimulus (the one 
with only 20% chance of being correct) were presented in novel pairings with all the 
other stimuli. During this phase subjects did not receive information about the 
outcome of their choice.  
  
Training pairs
80% correct 20% correct
70% correct 30% correct
40% correct60% correct
Acquisition phase
80% correct 70% correct
40% correct
60% correct80% correct
80% correct
Performance phase
Novel pairs
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4.2.1.2 MRI scanning 
The study was conducted at the Wellcome Trust Center for Neuroimaging at 
University College London using a 3T (Siemens TRIO) scanner equipped with a 
Siemens 12 channel phased array head coil. Anatomical images were acquired using 
modified equilibrium fourier transform T1 gradient echo scans, which were 
followed by 1-mm-thick axial slices parallel to the anterior commissure–posterior 
commissure plane. Functional scans used a gradient echo sequence; repetition 
time, 2.04 s; echo time 30 ms; flip angle 90 degree; matrix size 64 x 64; field of view 
192 mm; slice thickness, 2 mm and interslice distance factor was 1mm. A total of 30 
axial slices were sampled. The in-plane resolution was 2 x 2 mm.  
 
Functional imaging data were analyzed using statistical parametric mapping 
software (SPM5; Wellcome Trust Centre for Neuroimaging, London, UK; 
http://www.fil.ion.ucl.ac.uk/spm). During preprocessing, images were realigned 
with the first volume (after discarding six volumes to allow for T1 equilibration 
effects), and unwarped. For each subject, the mean functional image was 
coregistered to a high-resolution T1 structural image. This image was then spatially 
normalized to standard Montreal Neurological Institute (MNI) space using the 
“unified segmentation” algorithm available within SPM5 (Ashburner & Friston 
2005) with the resulting deformation field applied to the functional imaging data. 
These data were then spatially smoothed using an isotropic 6-mm full-width half-
maximum Gaussian kernel. 
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Acquisition phase of the task (scanning bouts 1 and 2 and laptop session 3) 
Scanning bouts 1 and 2, (acquisition phase of the task) lasted approximately 16 min, 
and consisted of 120 trials of 8s each. On each trial, two Hiragana characters 
appeared on the screen side by side, subjects completed the first two sessions in 
the fMRI scanner and the final session outside the scanner on a laptop in a well lit 
room. Subjects’ task was to select one of the characters on each trial by pressing 
either the right or the left key on a button box while in the scanner or the left or 
right keyboard shift key when using a laptop. The stimuli remained on the screen 
for 4 s, followed by presentation of the outcome (either ‘Correct’ or ‘Incorrect’) for 
2 s. The likelihood of being correct or incorrect was probabilistically determined for 
each stimulus (see above).  If subjects did not respond within the 4 s that the 
stimuli were on the screen the message ‘no key pressed’ was presented and the 
trial was excluded from the analysis. A fixation cross was presented for 2 s during 
the inter-trial interval (ITI). 
 
Performance phase of the task (scanning bout 3) 
Scanning bout 3 (performance phase) was 10 min long and consisted of 110 trials of 
6 s each. Similar to the acquisition phase, two Hiragana characters were presented 
side by side on each trial and subjects had to select one of the characters by 
pressing either the right or the left key. As before, characters remained on screen 
for 4 s. This time subjects did not receive feedback after making a response and the 
trial instead progressed immediately to the presentation of a fixation cross during 
the 2 s ITI. 
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Importantly, in addition the stimulus pairs used during training (80% with 20%, 70% 
with 30%, and 60% with 40%), the symbols were shown in eight novel pairings. Four 
of the pairings had the ‘best’ stimulus paired with all other stimuli (80% with 70%, 
80% with 60%, 80% with 40% and 80% with 30%), and the other four pairings 
compared the ‘worst’ stimulus to all other stimuli (20% with 70%, 20% with 60%, 
20% with 40% and 20% with 30%). All pairs were presented 10 times each in 
randomized order, resulting in 110 pairs overall.  
4.2.2 Data Analysis  
Reinforcement Learning Model 
We used a simple prediction error based reinforcement-learning (RL) model (Sutton 
1998) to predict a trial-by-trial measure of the stimulus values, and thus an 
outcome prediction error δ, which is defined as the difference between the actual 
outcome R (correct/incorrect = 1/0) and the expected value of the chosen stimulus 
(please see chapter 3 for full details). 
Trial-by-trial outcome prediction errors estimated by the model were then used as 
parametric regressors in the imaging data. 
fMRI analysis: whole-brain general linear model parametric analysis 
Acquisition session 
Functional MRI (fMRI) time series were regressed onto a composite general linear 
model (GLM) containing four regressors: trial onset time (the appearance of the 
hiragana characters), outcome onset time, motor response time and fixation cross 
presentation time. The outcome onset was parametrically modulated by the 
prediction error as estimated by the RL model (see above). We also composed 
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another GLM in which there were four regressors: correct trial onset time, incorrect 
trial onset time, motor response time and fixation cross presentation time. The 
actual value of the chosen cue in each trial was entered as a parametric modulator 
of the two trial onset regressors.  
  
Performance session: 
Four regressors were entered into the fMRI model: correct trial onset time, 
incorrect trial onset time, motor response time and fixation cross presentation 
time. The actual value of the chosen cue in each trial was entered as a parametric 
modulator of the two trial onset regressors.   
 
The regressors were convolved with the canonical HRF, and low frequency drifts 
were excluded with a high-pass filter (128-s cutoff). Short-term temporal 
autocorrelations were modeled using an AR(1) process. Motion correction 
regressors estimated from the realignment procedure were entered as covariates 
of no interest. Statistical significance was assessed using linear compounds of the 
regressors in the GLM, generating statistical parametric maps (SPM) of t values 
across the brain for each subject and contrast of interest. These contrast images 
were then entered into a second-level random-effects analysis using a one-sample t 
test against zero. 
 
Anatomical localization was carried out by overlaying the t-maps on a normalized 
structural image averaged across subjects, and with reference to an anatomical 
atlas (Naidich 2009).  All coordinates are reported in MNI space (Mazziotta et al 
1995).   
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Region of interest analysis  
We extracted data for all region of interest analyses using a cross-validation leave-
one-out procedure: we reestimated our main second-level analysis 12 times, always 
leaving out one subject. Starting at the peak voxel for the chosen cue value signal in 
ventromedial prefrontal cortex  and Nucleus accumbens , which was identified by 
looking over all correct trials  (in both the ON and OFF drug states), we selected the 
nearest maximum in these cross-validation second-level analyses. Using that new 
peak voxel we then extracted the data from the left-out subject and calculated a 
representative timecourse for each ROI as first eigenvariate from data in all voxels 
within a 4mm sphere around that peak. 
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4.3 Results 
Acquisition phase results 
As detailed previously, at the end of the acquisition phase, average choice accuracy 
and learning rates on the training pairs did not differ between groups in different 
drug states.  
In the neuroimaging data, we examined brain responses that correlated with 
outcome prediction errors computed from a reinforcement learning (RL) model, fit 
to subjects’ behavior during the acquisition phase. We found that bilateral 
responses in the striatum (central coordinates right putamen x=26, y=0, z=-4 left 
putamen x=-28, y=-12, z=-2) (figure IV.II A, B) strongly correlated with reward 
prediction errors, consistent with many previous results (McClure et al 2003a; 
O'Doherty et al 2003; Schonberg et al 2010; Schultz 1998; 2010; Schultz et al 1997). 
However, akin to our behavioral findings, we found no differences in prediction 
error related brain activation between the different drug states during acquisition 
(paired t-test ON compared with OFF; T (1,11) =-.076, p=0.46). When we examined 
positive and negative prediction errors separately we also did not find any 
differences between the different drug states (paired t-tests comparing positive 
prediction errors ON compared with OFF; T(1,11) =-.083, p=0.42; and comparing 
negative prediction errors ON with OFF, T(1,11) =-.051, p=0.614). Perhaps most 
surprisingly, at the time of cue onset we did not observe any correlation between 
brain activity and the value of the chosen cue in any of the drug states.  
118 
 
 
Figure IV.II: Prediction error related activity during acquisition. (A) Brain activity in 
putamen correlated with magnitude of outcome prediction errors across all trials 
during the acquisition phase. Activations are thresholded at p < 0.001 uncorrected. 
(B) Correlation (normalized effect size) between outcome prediction errors and 
BOLD activity in the two different drug states. Data in the ‘ON’ state was averaged 
across the 2 acquisition bouts performed in the scanner under this medication state 
and data in the ‘OFF’ state across the 4 acquisition bouts performed in this 
medication state. Error bars represent s.e.m.  
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Performance phase results 
In the performance phase we found that patients ON DRT performed significantly 
better than when they were OFF DRT in the novel pairings and crucially, a separate 
examination of the three drug states revealed a main effect of drug on performance 
but not on acquisition (see chapter 3). 
In order to investigate for neural mechanisms underlying the observed behavioral 
effects during the performance phase we tested for differences in the degree at 
which fMRI BOLD activity correlated with decision variables between different drug 
states. We tested if neural representations of stimulus values at the time of cue 
presentation differed between drug states. We found that BOLD activity in nucleus 
accumbens (central coordinates x = 8, y = 12, z = -4 ) correlated with the value of 
the chosen cue, but this effect was only evident in the ON medication state for  
correct trials (one sample t-test, T(1,11) =2.7, p=0.01). Cue evoked BOLD activity did 
not correlate with the value of the chosen cue when patients were OFF their DRT 
(one sample t-test, T(1,11) =0.98, p=0.34) or made an incorrect choice (one sample t-
test ON incorrect, T(1,11) =-2.12, p=0.06, OFF incorrect T(1,11) =-0.06, p=0.94) (figure 
IV.IIIA and IV.IIIB). We found an identical  effect in ventromedial prefrontal cortex (x 
= -2, y = 38, z = 0), where BOLD activity varied with the value of the chosen cue 
when patients were both ON medication and made the correct choice (one sample 
t-test, T(1,11) =2.52, p=0.02), but not when they were OFF their DRT (one sample t-
test, T(1,11) =0.31, p=0.76), or made an incorrect choice (one sample t-test ON 
incorrect, T(1,11) =-1.28, p=0.22, OFF incorrect T(1,11) =0.76, p=0.46) (figure IV.IIIC and 
IV.IIID). These findings show that activity in NAc and vmPFC successfully reflect the 
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values of the most rewarding cue only in an ON medication state, a characteristic 
that precisely mirrors patients’ improved performance in this state.  
121 
 
 
Figure IV.III: Brain activity correlating with the value of the chosen cue during the 
performance phase. (A) Brain activity in right NAc correlated with the value of the 
chosen cue. Analysis performed over all correct trials (both ON and OFF) in a context 
where novel parings are presented. (B) A differential analysis between drug states 
reveals that this correlation was selective to the ON state (p=0.01). (C) Brain activity 
in vmPFC also correlated with the value of the chosen cue. Whole brain analysis 
performed over all correct trials (both ON and OFF). (D) Similar to the activity in 
NAc, this correlation between BOLD in vmPFC and the value of the chosen cue was 
only evident in ON but not in OFF state (p=0.02). The error bars represent SEM. 
Thresholds in SPM images set to p < 0.005 uncorrected. 
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Although there were no differences in performance accuracy in the training pairs 
between the different drug states during the performance phase we checked 
separately for value related neural activity for these pairs during the performance 
phase. Akin to these behavioral findings and to the neuroimaging findings from the 
acquisition phase we did not find a significant correlation between BOLD activity 
and the value of the chosen cue in the training pairs during performance in either of 
the drug states. 
 
 
 
 
 
 
 
  
123 
 
4.4 Discussion 
Behaviourally I show an effect of dopamine replacement therapy (DRT) on the 
ability of PD patients to select the highest valued stimulus in a probabilistic 
reinforcement learning task. The medication status during the acquisition task 
phase did not impact on successful task learning and the critical factor in 
determining patients’ ability to select the best stimuli is the drug state during the 
performance phase, after the stimulus values have already been acquired 
successfully. Patients ON medication in the performance phase were significantly 
better at picking the best stimuli than when they were OFF medication irrelevant of 
the medication state they were in during the phase in which they acquired the 
stimulus contingencies. This effect was clearly seen in the novel parings and 
medication state did not impact performance when patients were required to 
select the best stimulus among pairs on which they had previously been trained.   
 
A mechanistic basis for the behavioural findings is provided by my fMRI data, that 
specifically addressed the neural representation of stimulus value during the 
performance phase. Even when subjects had learned stimuli OFF DRT, and only 
given their DRT after learning had occurred, activity in nucleus accumbens and 
vmPFC encoded the value of the chosen stimulus during the performance phase. 
This suggests that, in contrast to previous accounts (Bayer & Glimcher 2005; 
O'Doherty et al 2003; Pessiglione et al 2006; Schultz et al 1997), reduced dopamine 
availability during learning does not impair value acquisition. In keeping with this, I 
did not find any behavioural or neural differences between the different drug states 
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in the acquisition phase of the task. Instead, the data show that decreased 
dopamine during performance resulted in an impoverished neural representation 
of stimulus value. It is of interest that the two structures highlighted in the data, the 
nucleus accumbens and vmPFC, are strongly associated with various forms of value 
prediction and prediction errors in reinforcement learning contexts (Dreher et al 
2007; Luk & Wallis 2009; Matsumoto et al 2003). The pattern of findings observed, 
whereby stimulus value correlated with activity in these two regions in the ON 
state, implies that these brain areas can successfully represent the reward value of 
cues when patients are ON medication enabling successful performance for novel 
pairings. However, when this signal is degraded as seen in the OFF state, 
performance is impaired.   
 
The involvement of the NAc during successful performance is particularly notable, 
since this structure is well known to control the immediate effects of dopamine on 
numerous aspects of performance (Berridge 2009; Berridge & Robinson 1998; 
Ikemoto & Panksepp 1999; Lex & Hauber 2010). The NAc is a site where the 
predicted value of stimuli are transformed into preparatory Pavlovian responses 
under a modulatory influence of dopamine (Berridge & Robinson 1998). We suggest 
that a  preparatory response of approach is likely to be a key substrate for the 
behavioural patterns we observed in our task (Dayan et al 2006). This provides 
another reminder of the complexities inherent in a single neuromodulator 
(dopamine) supporting two apparently independent roles, namely reporting on 
appetitive prediction errors and influencing vigour (Boureau & Dayan 2011; Cools et 
al 2011; Ikemoto & Panksepp 1999; Niv et al 2007) . 
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A further important finding is the engagement of vmPFC in a context in which 
subjects made the correct choice between novel pairings of stimuli in the ON state, 
but not when subjects made incorrect choice in the ON state. This region is strongly 
implicated in valuation (Boorman et al 2009; Fitzgerald et al 2010; Gottfried et al 
2003; Kable & Glimcher 2009; Plassmann et al 2010; Seymour & McClure 2008) 
across a range of experimental manipulations, with mounting evidence pointing to 
a specific role when subjects have to choose between distinct options with different 
values (FitzGerald et al 2009; Padoa-Schioppa & Assad 2006; Wunderlich et al 
2010). This fits neatly with our observation that this region was engaged when 
subjects generated correct choices based upon an assessment of a learnt value 
difference between novel pairings. However, the data are intriguing in suggesting 
that the integrity of a dopamine input to this region is important for this form of 
value based decision. I acknowledge that I cannot be certain as to  its precise role 
but two possibilities are immediately apparent, either dopamine is necessary for a 
stable value representation that can support generalisation or alternatively 
dopamine is necessary for a  differencing operation needed when a subject, in the 
process of making a decision, needs to compare the value of distinct stimuli. I was 
unable to dissociate whether the neural value correlates were precursors to choice 
(action values) or the output of the choice process (chosen values) (Wunderlich et 
al 2009). It remains an open question for future research as to whether the deficit is 
due to a misrepresentation of pre-choice values and therefore due to a 
misrepresentation of values that are fed into a decision comparator, or a problem 
at the value comparison stage itself. Our study involved testing Parkinson’s disease 
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patients, which although provides the best human model of dopamine depletion, 
carries the problem of whether the observations in patients can be generalised to 
the healthy population.  Despite this caveat, the findings do lend support to the 
hypotheses (Berridge 2007; Berridge & Robinson 1998) and animal studies (Cannon 
& Palmiter 2003; Robinson et al 2005) which stress a major role for dopamine 
outside of learning. 
 
In this study I was able to separate out the effects on dopamine on learning from 
the effects on performance and we found that the main effect of dopamine 
replacement therapy appears to be on the performance aspect of the task. At the 
neural level the improved performance in the ON medication state was associated 
with enhanced  nucleus accumbens (NAc) and ventromedial prefrontal cortex 
(vmPFC) activity for the chosen cue value, an effect that was absent in the OFF 
medication state. The enhanced activity in the NAc and vmPFC in the ON 
medication state, which correlates with the improved behaviour, suggests that the 
enhanced cue value representation underlies the successful choice behaviour by 
allowing patients to select the best stimuli in novel contexts either by a more stable 
cue value representation or by improving the ability to compare the values of 
stimuli.  
 
In summary, the improved performance in patients ON medication is not due to an 
effect of medication on learning and reflects a different effect of dopamine such as 
Pavlovian appetitive approach or motivational vigour associated with improved 
neural representation of cue value in a high dopamine state. By isolating the 
processes on which dopamine has the greatest impact, my findings point to likely 
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mechanisms that underlie common behavioural deficits seen in PD patients, both 
clinically and in various laboratory tasks, as well as providing a basis for future 
cognitive oriented therapies as well as shedding light on the fundamental role 
played by dopamine in reinforcement learning.  
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Chapter 5  
The effect of valence on 
movement: a study of 
bradykinesia in Parkinson’s 
disease 
 
The experiment described in this chapter focuses on the motor deficits observed in 
PD. The aim of this study was to test whether movement speed in Parkinson’s 
disease (PD) patients can be modulated by the specific nature of the motivational 
salience of possible action-outcomes, putatively demonstrating a link between the 
motor and cognitive deficits observed in PD. 
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5.1 Introduction 
Akinesia is a cardinal feature of  Parkinson’s disease (PD)(Edwards 2008), consisting  
bradykinesia (slowness in executing movements), poverty of movement and a 
decrement in the size of repeated movements. Despite its impact, the precise cause 
of bradykinesia remains the subject of debate, with no single hypothesis providing a 
fully comprehensive account (Berardelli et al 1986; Hallett & Khoshbin 1980; 
Montgomery & Nuessen 1990; Sheridan & Flowers 1990; Sheridan et al 1987; 
Teasdale et al 1990).  
 
Recent empirical findings and theoretical accounts suggest that bradykinesia, rather 
than being simply a manifestation of motor slowness, might reflect a specific deficit 
in the operation of motivational vigour in the striatum (Mazzoni et al 2007; Niv et al 
2007; Niv & Rivlin-Etzion 2007). For example, compared with controls, PD patients 
could achieve similar speeds and accuracy of reaching movements, but did so more 
rarely, putatively demonstrating an implicit ‘reluctance’ to move fast (Mazzoni et al 
2007).  
 
A speeding effect of dopamine on action in response to rewards has been widely 
described (Moustafa et al 2008; Niv et al 2007; Salamone & Correa 2002). However, 
the effect of dopamine depletion on punishment avoidance is much less well 
understood and has not been formally tested in humans. One of the striking clinical 
characteristics of bradykinesia in PD is its variability (Blin et al 1990; Sheridan et al 
1987), with the same patient being able to achieve very different movement times 
in different contexts. An extreme manifestation of this variability is “kinesia 
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paradoxical” where patients are suddenly able to move at near normal speeds, 
which usually occurs only in extreme aversive contexts (Critchley 1929; Rahman et 
al 2008). This class of observation motivated me to examine if winnable rewards 
and avoidable punishments might have differential effects on movement time. 
Furthermore, a differential effect would shed light on valence and vigour 
opponency between dopamine and its putative opponent (Boureau & Dayan 2011; 
Cools et al 2011; Daw et al 2002). 
 
The use of rewards and punishments furnished me with an opportunity to test 
whether there is an effect of dopamine depletion, as manifest in the Parkinsonian 
state, on an ability to maintain a response plan or working memory trace in the face 
of distraction and whether this is valence specific. This in principle could explain 
some of the conflicting findings in the literature: PD patients are impaired when 
required to ‘multitask’ motor and cognitive tasks (Hausdorff et al 2003; Praamstra 
et al 1998; Shohamy et al 2006), although when working memory is explicitly 
tested, dopamine depletion reduces distractibility (Cools et al 2010; Crofts et al 
2001).  However in these tasks outcome valence was not explicitly manipulated, 
leaving unresolved the question of whether an impact of distraction may be context 
(valence) sensitive.  
 
I developed a novel movement time paradigm involving winnable rewards and 
avoidable electric shocks, and tested PD patients and matched controls. Critically, I 
assessed movement time and not reaction times. The motivation here was to 
remove any confound of cueing, given the known sensitivity of PD patients to visual 
and auditory cues (Brown & Marsden 1988; Lewis et al 2000). Additionally, I was 
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specifically interested in measuring the time it takes to execute as opposed to 
initiate a movement, thereby focusing on the core deficit found in bradykinetic 
patients. In my paradigm, the faster the subjects performed an action the more 
likely they were to win money (in appetitive blocks) or to avoid an electric shock (in 
aversive blocks). I compared patients when OFF dopaminergic medication with 
controls. This means I tested patients in a more natural disease state, minimising as 
far as possible the effect of medication fluctuations and dose variations. 
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5.2 Materials and methods 
5.2.1 Subjects  
Twenty three adults (12 PD patients and 11 healthy control subjects) participated in 
the study, whose procedures were approved by the National Research Ethics 
Service, Moorfields & Whittington Research Ethics committee. Patients were 
recruited from the movement disorder clinic at the National Hospital for Neurology 
and Neurosurgery (NHNN).  Control subjects were recruited through 
advertisements in public libraries or were spouses of patients. Written informed 
consent was obtained from all subjects and transport costs associated with 
participation were reimbursed. The participants were paid an extra fee of between 
£5 and £15 which was dependent on task performance.  
Subjects were screened for psychiatric and neurological co-morbiditiy as well as 
current and past medication. They were also examined by a clinician and asked to 
complete several questionnaires, including a depression scale, an impulse control 
disorder screening questionnaire, and a mini-mental state examination.  
5.2.1.1 Subjects with Parkinson’s disease  
Twelve English speaking early- to moderate-stage [H+Y stage- mean (SE) 2.4 (0.14)] 
(Hoehn & Yahr 1967) PD patients (eight males) aged between 48 and 82 years 
[mean (SE) 66.6 (2.6) years] participated in, and completed, the study. Eleven of the 
subjects were right-handed. They had on average (SE) 13.25 (0.66) years of 
education. Initial diagnosis of Parkinson’s disease varied from 3 to 9 years [mean 
(SE) 5.45 (0.7) years]. There was no history of other major neurological or 
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psychiatric disease. Patients were on various regimens of anti-Parkinsonian 
medications; 11 subjects were taking carbidopa/levodopa combinations; one was 
receiving dopamine receptor agonists alone. Total daily dose of carbidopa/levodopa 
varied from 75/300mg to 250/1000 mg [mean (SE) 117/468 (19.6/78.7) mg]. (see 
table 5.5.1 for details of other medications) .  
5.2.1.2 Control subjects  
Eleven English speaking control subjects (six males) aged between 38 and 73 years 
[mean (SE) 61.72 (3.1) years], with no current major health problems or history of 
neurological or major psychiatric illness, participated in, and completed ,the study. 
Nine of the subjects were right-handed. They had on average (SE) 14.2 (0.8) years of 
education. Current medications included anti-hypertensive drugs (three subjects), 
lipid-regulating drugs (three subjects) and antidepressants (one subject) (table 
5.5.1). 
5.2.2 Experimental Paradigm  
Both groups completed the computerized movement time task detailed below. 
Subsequently, subjects completed a battery of neuropsychological tests, 
comprising: (i) the Mini Mental State Examination to assess cognitive impairment 
(Folstein et al 1975); (ii) the Beck Depression Inventory (Beck et al 1961); and (iii) an 
impulse control disorder questionnaire (adapted from (Weintraub et al 2009)). In 
addition, the severity of clinical symptoms was assessed in the Parkinson’s disease 
(PD) group according to the Hoehn and Yahr (Hoehn & Yahr 1967) five-point rating 
scale, and using the Unified Parkinson’s Disease Rating Scale (UPDRS – all sections) 
(Fahn S 1987).  Parkinson’s disease subjects completed one test session in the 
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relative ‘OFF’ medication state, following a minimum of 12 hours withdrawal from 
all dopaminergic medication and omission of all slow release preparations for a 
minimum of 18 hours. The average Hoehn and Yahr rating for the patients was 2.4 
[mean (SE) 2.4 (0.14)] and UPDRS was 48.5 [mean (SE) 48.5 (3.6)]. PD patients and 
controls were well matched for age (F(1,21)=1.44, p=0.242 ), education (years) 
(F(1,21)=0.87, p=0.361) and  MMSE (F(1,21) = 0.48, p=0.495). PD patients had 
higher BDI and ICD scores however when compared to controls the differences only 
reached trend level significance (BDI (F(1,21)=3.39, p=0.08 and ICD (F(1,21) = 3.05, 
p= 0.095) (table 1)), we acknowledge however that this may be due to the small 
sample sizes. Parkinson’s disease patients and controls were well matched in terms 
of age, education, sex, and on their neuropsycological test scores (see table 5.5.2). 
Control subjects also completed one test session. 
5.2.2.1 Movement time task 
Stimulus presentation and response recordings were conducted using Cogent 
software (www.vislab.ucl.ac.uk), programmed in Matlab (Natwick, MA). The task 
was designed to measure movement times in response to stimuli associated with 
rewarding or punishing outcomes. There were two types of trials: trials in which 
participants’ aim was to win money and trials in which the aim was to avoid shocks. 
The task consisted of 6 interleaved blocks of 50 trials each, with blocks of ‘money’ 
trials alternating with blocks of ‘shock’ trials. The first block type was randomised 
between subjects. 
Trials began with presentation of either a money or shock symbol for 2 seconds. 
The symbols were presented on a blue or yellow background, corresponding to 
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trials in which subjects could win money or trials where they should avoid shocks. 
This indicator of context was designed to remind participants of the current trial 
type. Background colours were counterbalanced across subjects. Participants were 
instructed to refrain from any action while the symbol remained on the screen. 
When the symbol disappeared, they were then required to press a key on the 
keyboard to start the trial. The trial would only start when the first key was pressed. 
Trials were self-paced. I opted for this design specifically to prevent the start of the 
trial being explicitly cued, in the light of the known effect of cueing in PD. (Brown & 
Marsden 1988; Lewis et al 2000)  After commencing a trial, by pressing the first key, 
subjects then needed to press an adjacent key on the keyboard, using the same 
finger, in as quick a time as possible. On half of the trials (both in the money and 
shock trials), after the first key was pressed, a green flashing box appeared mid 
screen, which subjects were instructed to ignore. The role of this flashing box was 
to provide an attentional distractor.  The flashing box remained on the screen until 
the trial was terminated by the second button press (see figure V.I for task 
depiction).  
The time between the first and second button press was defined as the movement 
time. Following the second button press (i.e. completion of the trial), a screen was 
shown indicating trial outcome. In the ’money’ blocks, participants either did or did 
not win 10p. In the ‘shock’ blocks, participants either avoided or received a shock. 
To incentivise fast movements, encouraging subjects to perform actions at maximal 
speed, and to reduce habituation, I varied the probability of outcomes (between 0.2 
and 1 in an identical fashion for all subjects) such that receipt of reward or the 
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omission of punishment was linearly dependent on the speed of the associated 
movement time.   
Subjects first performed a short practice session in order to familiarise themselves 
with the task. The instructions for the task were presented on the computer screen.  
During the practice session they neither received shocks nor won money.   
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Figure V.I: Schematic of the movement time task 
Trial types are illustrated as a function of outcome valence (yellow for money trials 
and blue for shock trials) and presence or absence of a distractor (green flashing 
square). There were two possible outcomes in the money trials; ‘you have won 10p’ 
or ‘you have not won 10p’ and there were two possible outcomes for the shock 
trials; ‘you will now receive a shock’ or ‘you will now not receive a shock’. Subjects 
were exposed to 4 distinct trial types (see methods for details) comprising 
(i) money trial without distractor,  
(ii) money trial with distractor,  
(iii) shock trial without distractor,  
(iv) shock trial with distractor. 
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Failure to complete a trial correctly, for example by pressing the same button twice 
in error, resulted in no outcome being delivered (i.e. no money or shock outcomes). 
Although it is conceivable that subjects could have used this as an ‘escape route’ 
from aversive outcomes, when I tested this possibility explicitly I found that 
subjects failed to carry out trials only on very few occasions during testing [mean 
(SD), 2.47 (4.35) from a total of 150 trials]. Failure to respond on one trial did not 
impact on movement time on subsequent trials and mean movement time before, 
and after, this contingency was utilised did not differ significantly (TTEST p>0.2).  
5.2.2.2 Apparatus  
Participants were seated in a well-lit room in front of a desktop computer with a 
normal keyboard.  
Electric skin stimulation  
Two Digitimer boxes were fitted with circular electrodes. The triggers for the shock 
box were sent via the parallel port to the input on the shock box. Before 
commencing the task, participants had an electrode attached to the back of their 
non-dominant hand. They then underwent a shock titration procedure. This 
consisted of first establishing a maximal threshold level at which the electrical 
current was rated as very uncomfortable. Then, an automated staircase procedure 
was used to determine the level of shock for each individual that was 60% of their 
own maximal threshold.  
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5.2.3 Data Analysis  
I initially focused on the overall effects of disease on movement time in the task, 
examining the differences in performance in the money versus the shock trials, and 
comparing the effects of these outcomes with those obtained in the control group. 
I also examined effects of previous trials’ outcomes on the movement times of 
subsequent trials by performing multiple regression analysis. Here I modelled 
separately the modulatory effects of receiving money compared with not receiving 
money on the previous trial; and the effects of receiving shock compared with not 
receiving a shock on the previous trial. I also included terms for the overall average 
effect on movement time of money and shock trials, anticipating that these would 
be different. I estimated the betas from the regression model and performed one 
sample t-tests on these at the group level to make inferences about the effect size 
of four factors: 
MT=β1 x Money + β2 x Shock + β3 x M (t-1) + β4 x S (t-1) + β5 x D(t) + ε 
Where:   
MT = movement time 
Money = indicator variable for all money reward trials 
Shock = indicator variable for all shock punishment trials 
M(t-1)=  indicator (1/-1) of outcome of previous money trial 
S (t-1) = indicator (1/-1) of outcome of previous shock trial 
D(t) = indicator (1/-1) of whether distractor present. 
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 ε = error term 
All terms were entered simultaneously into the regression (without being 
orthogonalised). 
Additionally, I performed an ANOVA examining the effect of the distractor on 
movement times, testing for a 3-way interaction between block type 
(money/shock), distractor (present/not present) and group (controls/patients). I 
also looked at the time taken from the appearance of the money or shock symbol 
until the first button press. This was in order to confirm that there was no 
difference in movement time between the two groups or valence conditions which 
could indicate differences in motor preparation times.  
I excluded 2 sessions (one money session in a control subject and one shock session 
in a patient) where movement times in the first block were over 150% longer than 
the movement times in subsequent blocks for the same type of trial. I believe this 
incongruous performance in these subjects reflects an initial failure to understand 
the task demands which led to performance changing drastically between the first 
and subsequent blocks.  
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5.3 Results 
My analysis indicated two main effects. First, I found an effect of group whereby 
patients were slower overall than controls F(1,21)=15, p=0.001  . Second, I found an 
effect of valence such that both patients and controls were faster for shock 
compared to money trials (paired t-tests comparing money with shock trials in 
controls T(1,10) =2.51, p=0.03 ; and in patients T(1,11)=3.49, p=0.005) (figure V.II, table 
5.5.3). 
 
Figure V.II: Movement times raw numbers 
Average movement times (ms) for money trials and shock trials for controls (blue 
bars) and patients (red bars). Error bars represent (two times) the standard error. 
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Crucially I observed an interaction between group (control/patients) and outcome 
valence condition (shock/money) F(1,21)=6.6, p=0.017.  The interaction was 
characterised by a bigger difference in movement time (MT) between money trials 
and shock trials in patients compared with controls (figure V.III).  
 
Figure V.III: Differences in movement time in money compared with shock trials 
Movement time (ms) in money trials minus movement time in shock trials for 
controls (blue bars) and patients (red bars). Error bars represent (two times) the 
standard error of the difference. 
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I next examined the effect of outcome in a previous trial on movement time in the 
subsequent trial. I hypothesised that movement times would be influenced both by 
context (i.e. money compared with shock trials) and also experience on a previous 
trial, evident in a trial-by-trial sensitivity to rewards and punishments. For example, 
I expected that failure to achieve the desired outcome (i.e. not winning money or 
actually receiving a shock) on a previous trial would lead to faster movement on the 
subsequent trial.  This is exactly what I found for the control group in the case that 
they failed to win money (T(1,10)=-2.23, p =0.049 two tailed) . However, this speeding 
effect was absent in patients (T(1,11)=-1.23, p=0.242 two tailed) (p>0.25). Both 
patients and controls responded in the same manner to receipt of a shock by 
tending to improve their speeds in the trials following shocks. However, this 
speeding was not statistically significant.  
To ensure that the faster responding for shock in the patient group could not be 
explained by a prolonged motor preparation time, I examined the time taken from 
the symbol appearance to the first button press. There was no significant difference 
in this initial period of time between the groups (patients /controls) F(1,21)=0 
(p=0.9997) or conditions (shock /money) F(1,21)=0.49 (p=0.464) or an interaction 
between group and condition F(1,21)=2.5 (p=0.138) ruling out this possibility . 
A differential effect of distractor on movement time was evident. In the repeated 
measures ANOVA there was a significant 3 way interaction between block 
(money/shock), distractor (present/not present) and group (controls/patients) (F 
(1,20) = 7.54 p=0.012) characterised by patients’ movement time  slowing when 
performing a shock trial where a distractor was present (figure V.IV) 
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Figure V.IV: Effect of distractor on MT 
Movement time (ms) in trials with a distractor present minus movement time with 
no distractor present, for money trials and shock trials, for controls (blue bars) and 
patients (red bars). Error bars represent (two times) the standard error of the 
difference. 
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The multiple regression analysis allowed me to look for more subtle differences in 
the modulatory effect of previous trials on movement time in the two groups while 
controlling for other factors. This confirmed my findings that not winning money in 
a previous trial had a significant effect on movement time in the control group (one 
sample t-test p<0.001 two tailed. β3 (controls: effect of loss at t-1):  mean (SE) 3.86 (0.7)), 
showing that controls sped up significantly on a trial after they failed to win money. 
This speeding effect was absent in patients (one sample p>0.4, two tailed β3 (patients: 
effect of loss at t-1):  mean (SE) 2.15 (2.7)).  
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5.4 Discussion 
The most notable result is a valence asymmetry in the movement time of PD 
patients. This comparative failure to speed up in order to win rewards is consistent 
with previous findings in PD patients OFF medication (Moustafa et al 2008) and 
supports proposals that tonic dopamine levels control the rate and vigour of 
movements, possibly by signalling the average reward rate in the environment (Niv 
2007; Niv et al 2007). This  notion has been linked to the idea of impaired ‘motor 
motivation’ in PD, whereby there is a shift in the cost/benefit ratio of moving fast 
(Mazzoni et al 2007). Crucially, I find that although the response to rewards appears 
impaired in the PD group, the trial-by-trial response to punishments is not similarly 
impacted, a fact which has not previously been demonstrated. This finding 
highlights that in PD, dopamine depletion has a lesser impact on responses to 
punishments compared to rewards, and hints at a more complex role for dopamine 
in active avoidance. A critical aspect to the task is that I examined the effect of 
explicit contexts on movement time and compared subjects in dopamine depleted 
and non-dopamine depleted states. My findings indicate that bradykinesia is not 
simply related to movement, but rather to the way in which a hypodopaminergic 
striatum computes action values.  
 
Importantly, I observed a difference in the effect of past monetary loss on 
subsequent actions in patients compared with controls, where subjects were given 
trial-by-trial feedback on whether their performance sufficed to merit a reward or 
avoid a punishment. If learning is effective, I expected a speeding up of movements 
following trials with negative outcomes (failure to win money or avoid a shock), 
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thereby improving the chances of achieving the desired outcomes on subsequent 
trials. This effect was clearly evident in the control group for rewards, but was 
absent in the PD patients. Patients did not speed up their movements after failing 
to win a reward despite physically being able to move faster, a fact they clearly 
demonstrated in the shock avoidance trials. The observation of failure to adjust 
movement time in the face of monetary loss in PD patients tallies with findings of 
impaired reward feedback learning in PD patients OFF medication (Czernecki et al 
2002; Frank et al 2004). Of note, this trial-by-trial adaptation, whereby subjects 
speed up in response to a failure to win money has been observed previously albeit 
in the context of a probabilistic task in which this speeding was evident in both 
controls and patients (Moustafa et al 2008). 
Finally, I found a detrimental effect of a distractor that was only evident in the 
shock trials in PD patients, indicating that here too there is an asymmetrical effect 
of valence. The context specificity of distraction has been demonstrated previously, 
with susceptibility to distraction being higher in PD patients when multitasking is 
required (Hausdorff et al 2003; Praamstra et al 1998; Shohamy et al 2006)  but 
lower in working memory tasks when OFF medication (Cools et al 2010; Crofts et al 
2001). Here I show that distraction is also valence specific. Given that PD patients 
can improve both their motor speed and accuracy of their movements with 
increased attention (Baker et al 2007; Cunnington et al 1995), I hypothesised that 
the hypodopaminergic state in PD led to decreased attending to appetitive stimuli 
compared with aversive stimuli, improving motor performance at the cost of an 
increased sensitivity to distraction in the aversive trials.  
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In summary, I provide evidence that bradykinesia is not a fixed, context-
independent, deficit.  I link the cognitive and motor deficits associated with the PD 
hypodopaminergic state by demonstrating that bradykinetic movements are 
dependent on the valence frame in which movements are executed.  Such 
modulation is apparent in “kinesia paradoxical”, where PD patients can suddenly 
move quickly in exceptional circumstances (Critchley 1929; Rahman et al 2008) or 
indeed (though less closely associated with the theory) when explicit visual or 
auditory cues are present (Suteerawattananon et al 2004). Here I showed this effect 
in a controlled environment with conventional cues whose motivational salience is 
internally rather than externally assessed. Additionally I demonstrate that 
distractors play an important role in performance in PD patients and that this effect 
is also valence specific. These data have clinical implications, potentially yielding 
new strategies to increase the effectiveness of rehabilitation treatments.  
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5.5 Appendix  
Table 5.5.1: Medications 
 Patients (n=12) Controls (n=11) 
Sinemet (carbidopa-levodopa) 11 0 
Stalevo (carbidopa-levodopa-entacapone)  1 0 
Ropinirole 4 0 
Trihexiphenidyl 1 0 
Selegiline 2 0 
Pramipexole 1 0 
Co-Q10 1 0 
Clonazepam 1 0 
Anti-hypertensives 2 4 
Anti-depressants (SSRI/SNRI) 1 1 
Warfarin 1 0 
Terazosin 1 0 
Thyroxine 1 0 
Statin 1 3 
Ceterizine 1 1 
Aspirin 1 2 
SSRI = selective serotonin reuptake inhibitor. SNRI = Serotonin–norepinephrine 
reuptake inhibitors 
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Table 5.5.2: Neuropsychological data sets 
 Patients (n=12) Controls (n=11) 
Age 66.6 (2.6) 61.7 (3.1) 
Education (years) 13.2 (0.6) 14.2 (0.8) 
MMSE 28.5 (0.3) 28.9 (0.4) 
BDI 10.2 (1.5) 6.1 (1.5) 
ICD 2.25 (0.7) 0.63 (0.54) 
Values represent mean (SE). BDI = Beck Depression Inventory; MMSE=Mini Mental 
State Examination; ICD = impulse control disorder questionnaire. 
Table 5.5.3: Raw data 
 Patients (n=12) Controls (n=11) 
Mean MT money trial 305.8 (23.5) 226.7 (10.9) 
Mean MT shock trial 278.6 (21.2)  221.2 (11) 
Mean MT distractor 
money trial 
304.4 (23.2) 228.2 (11.2) 
Mean MT no distractor 
money trial 
307.1 (23.2) 225.2 (10.8) 
Mean MT distractor  
shock trial 
277.2 (21.7)  220.4 (10.4) 
Mean MT no distractor 
shock trial 
269.9 (23.3) 221.8 (11.6) 
Values are in milliseconds and represent mean (SE).  
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Chapter 6  
Expectations and violations: 
Probing the role of dopamine in 
set shifting   
 
The experiment described in this chapter focuses on the role of dopamine in set 
shifting. I used a pharmacological manipulation in healthy individuals to isolate the 
role of dopamine in set shifting while controlling for executive aspects of motor 
vigour and for responses to non-specific violations of sensory predictions, with the 
hope of better understanding the neurobiology underlying pathological behaviours 
associated with the hyperdopaminergic state.  
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6.1 Introduction 
The aim of this study was to characterise the role of dopamine in set switching. 
Specifically, I measured the effects of (L-dopa) manipulation of dopaminergic 
neurotransmission on behavioural and neurophysiological responses to cues calling 
for a change in response set.  
 
In brief, subjects were required to switch sets between a go and a no-go response, 
when they encountered an unexpected outcome following sequential presentations 
of the same target stimulus. Alternating between go and no-go sets enabled me to 
average over behavioural and physiological responses that did and did not involve 
motor activity and thereby focus on set switching per se, independent of action. 
Furthermore, by comparing responses to unexpected losses with unexpected null 
outcomes, I was able to study the role of dopamine in modulating responses to 
cues with (negative) valence, as opposed to a non-specific violations of sensory 
expectations. 
 
The motivation for this work rests on the observation that dopamine may be 
essential for high-level set switching and action selection, as evidenced by studies in 
normal subjects (Mehta et al 2004) and Parkinson's disease (Cools 2006; Cools et al 
2001a). In this setting, I was interested in how the neuromodulatory effects of 
dopamine may be implicated in set switching and the maintenance of an 
appropriate representation of contingencies in working memory. This is in 
contradistinction to the role of dopamine in signalling rewards or outcomes per se.  
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To characterise set switching behaviourally, I measured the number of correct 
responses following an outcome that indicated a reversal of contingencies (i.e. a set 
shift). In terms of the physiological responses underpinning set switching itself, I 
used fMRI to measure the responses to (surprising) outcomes at the point of 
reversal. These responses were quantified in relation to the immediately preceding 
trial, in which predicted expectations were fulfilled. In short, I used the 
neurophysiological response to violations (surprising or unexpected losses) to 
measure the neuronal activity responsible for a switch in response set. I then 
examined the effect of perturbing dopaminergic neurotransmission with L-dopa on 
these behavioural and physiological responses. 
 
 My hypothesis was that the L-dopa would impair set switching and, behaviourally, 
decrease the proportion of correct responses on the trial following reversal. 
Specifically, I predicted that this decrease would be greater when avoiding losses, 
as opposed to avoiding null outcomes in similar fashion to that which has been 
previously been found in PD patients ON dopaminergic medication (Cools et al 
2006). Physiologically, I predicted that during sequential cued responses (in both go 
and no-go contexts), the succession of cues and contingent responses would be 
encoded by delay period activity in the prefrontal cortex. The itinerant dynamics of 
these high-level central pattern generators are selected and maintained by 
dopaminergic gating of cortico-striatal interactions (Frank & Claus 2006; McNab & 
Klingberg 2008). When expectations about outcomes are violated, this itinerant 
(attractor) activity is destroyed and a new (metastable) dynamical representation 
emerges (Friston 1997; Oullier & Kelso 2006; Rabinovich et al 2008). Dopamine 
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plays an important modulatory role in working memory, specifically via D1 
receptors, and is thought to be central in maintaining robustness of working 
memory representations making them more resistant to distractors (Durstewitz et 
al 2000).  We assume that in our study, the switching between metastable 
attractors rests upon a de-modulation of ongoing attractor dynamics by dopamine, 
when expectations are violated. In other words, an unexpected outcome (that 
signifies a change in contingencies) causes a reduction in mesocortical 
dopaminergic modulation of prefrontal activity, allowing for the emergence of a 
new pattern of firing and consequent set shifting. In summary, I predicted a 
reduction in prefrontal responses to unexpected outcomes (losses) that reflects a 
suppression of itinerant (working memory) activity which is known encoding 
contingencies that are no longer consistent with sensory input.  
 
The functional anatomy of these effects should, I predicted, be expressed in the 
projection fields of the ascending dopaminergic projections from the substantia 
nigra and ventral tegmental area: namely, the striatum (nigrostriatal pathway), the 
medial prefrontal cortex (mesocortical pathway) and nucleus accumbens 
(mesolimbic pathway) (Arias-Carrion & Poppel 2007; Haber 2003; Robbins 2000). 
My primary hypotheses concerned reductions in prefrontal responses at the point 
of reversal (i.e., to surprising or unexpected outcomes). However, I hoped to see 
similar or reciprocal subcortical responses. 
 
I therefore first tested for a violation effect throughout the brain, in the hope of 
identifying significant responses in these regions (by comparing trials with 
unexpected outcomes with the preceding fully predicted trial), while using a fully 
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balanced design to control for any effects of executive aspects of motor vigour and 
non-specific sensory surprise on these representations. I then tested for the effects 
of dopamine within these regions, anticipating that violation-dependent effects 
would be attenuated under L-dopa. This is largely what I found; however, to my 
surprise L-dopa actually reversed the violation or surprise-dependent decreases in 
prefrontal responses.  
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6.2 Materials and Methods 
The study and its procedures were approved by the UCL Research Ethics 
Committee. 
6.2.1 Participants 
All participants gave written informed consent.  Only male participants were 
included to avoid menstrual cycle-dependent interactions between gonadal 
steroids and the dopaminergic system (Becker & Cha 1989; Dreher et al 2007). 
Sixteen men [age mean (SE) 23.8 (1.65)] completed the study. Two subjects (not 
included in the above analysis), one in the dopamine session and one in the placebo 
session were excluded due to excessive drowsiness leading to very low response 
rates during the scanning session.  
 
15 of the subjects were right-handed and one was left handed. All were fluent 
English speakers with no history of other major neurological or psychiatric disease 
and no concurrent medication use.  
6.2.2 Stimuli and task 
I used a novel set switching task (see task depiction). Stimuli consisted of one of 4 
Hiragana symbols presented in white fonts on a black background. All trials 
followed a similar sequence. Initially, a stimulus was shown on-screen for 200msec, 
before being masked (by a composite of all 4 Hiragana symbol characters) for a 
further period of time determined by the subject by subject reaction time (RT) 
measurement (see below). Subjects were required to make an appropriate 
response following stimulus presentation, either gripping (‘Go’) or omitting a grip 
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response (‘NoGo’). After the individualised RT had elapsed, a coloured border 
appeared (500msec) indicating the type of response made on that trial. If subjects 
gripped, a yellow border appeared around the stimulus and if they did not grip a 
blue border appeared. This was to provide feedback to the participants so they 
could assess whether their intended responses were performed adequately within 
the allocated time (so that they know to adjust their behaviour if their gripping is 
not fast/strong enough).  Following the feedback screen subjects were presented 
with an outcome screen (750 msec) which was different depending on which type 
of block the subjects were performing. In the ‘null’ block subjects could either 
continue to receive or not receive one pound (represented by a pound coin or an 
empty circle), in the ‘avoid loss’ block subjects could either not lose or lose one 
pound (represented by an empty circle or a pound coin picture with a cross through 
it), before commencement of the next trial.  
 
Blocks of sequential trials were undertaken, lasting 17 min. There were two types of 
block, grouped according to the possible feedback subjects could receive following 
response execution. In block type 1 (‘null’ blocks), surprising set shifts were 
signalled by null outcomes (a blank circle). Conversely, in block type 2 (‘avoid loss’ 
blocks), surprising set shifts were signalled by salient loss outcomes (a cross 
overlying a pound coin). Correct responses in null blocks were signalled by a pound 
coin picture; in avoid loss blocks correct responses were indicated by a blank circle.  
These outcomes pertained to real monetary reward (see reward schedule below). 
Critically, because set shifts were rare events and the contingencies were entirely 
deterministic rather than stochastic, participants formed a strong expectation of 
158 
 
performing correctly and receiving expected feedback. In addition, by using fully 
deterministic outcomes we ensured that minimal learning was required to 
successfully alter behaviour, thereby allowing us to focus on the effect of a set shift 
and not on learning effects. Although it would seem that this method does not 
easily allow for separation of the set shift from the outcome, the behavioural trial 
of interest was actually the trial after the unexpected outcome thereby eliminating 
this problem. In the imaging data we focussed on the two trials preceding the 
switch and were specifically interested in examining the neural responses to fully 
expected outcomes and contrasting them with fully unexpected outcomes. In the 
imaging data we did not in fact examine the trial in which behaviour changed, only 
the brain responses which preceded the behavioural change. Moreover, running 
null and avoid loss contingencies in separate blocks entrained vigorous prepotent 
responses and avoided rapid contextual changes. 6 blocks were run in total (3 ‘null’ 
3 ‘avoid loss’ blocks). 
 
 Occasionally, contingencies for the pair of stimuli in each block would switch with 
each other (‘set switch’). On these trials a stimulus for which subjects previously 
had to grip (Go response) became a stimulus for which they had to not grip and 
vice-versa. To ensure that set shifts were unpredictable and that subjects had fully 
understood the contingencies before a set shift, I set a minimum constraint of 5 
correctly executed  trials (10 before the first set switch) per contingency mapping 
before a set switch was permitted. On trials subsequent to this, there was a 50% 
probability of switch per trial. 
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6.2.3 Procedure 
Overview 
We employed a within-subjects design, with each patient attending twice.  All 
subjects performed the task in two different drug states, either on placebo (Cacit 
1.25- contains 500mg calcium) or L-dopa (Madopar 187.5 mg contains 150mg 
Levodopa).  This order was randomised, and sessions were scheduled a minimum of 
one week apart to ensure complete drug washout. Different Hiragana symbols were 
used for each visit (see figure VI.I for details of the task). The L-dopa and placebo 
were mixed with orange squash and both the participants and the investigator were 
blinded to the order of the drug/placebo. After ingestion, participants waited for 60 
minutes to ensure maximum peak plasma drug concentration according to L-dopa 
pharmacokinetics (Khor & Hsu 2007). Participants performed both sessions at the 
same time of day to control for any diurnal fluctuations in baseline 
neurotransmitter levels. 
 
Reaction time measurement 
On the first visit, prior to L-dopa/placebo administration, baseline grip reaction 
times were measured to calibrate the subsequent set switching task. The task set-
up was similar to the general trial sequence for the switch task. Two fractals were 
presented, one cueing a fast grip and one requiring omission of a grip response. 
These contingencies were explicitly described before commencing the task, and 
feedback was given following each response. The average +/- 2  standard deviations 
of RT (of grip trials), averaged over 15 presentations was used as the upper 
threshold time for a response in the set switch task. This controlled for intrinsic 
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within subject variability in response speed. Average individualised RT’s (including 2 
standard deviations of the mean were: [Mean (SE) 620ms (35.2)]. 
 
To familiarise subjects with the structure of the task they undertook a short 
practice block before scanning began in both sessions. During the practice session, 
subjects performed the identical task, except with different Hiragana symbols. 
 
Payment schedule 
On one of the days, after the scanning was completed, subjects underwent a 
structural scan. On the second session after task completion subjects received 
payment. To ensure incentive compatibility (i.e. so that subjects knew that each 
trial had the potential for real monetary loss or gain) 15 trials of each block type 
were randomly selected across sessions and paid out for real.   
 
Set switching task  
Each of 3 scanning runs lasted approximately 17 min, and consisted of 2 blocks ,one 
in which the aim was to avoid null outcomes and one in which the aim was to avoid 
monetary loss, in randomised order.   
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Figure VI.I : Task depiction. Above is an example of a grip to avoid loss trial in the 
task. The subject grips in response to the Hiragana character and then receives 
feedback that the grip has been registered (indicated by a yellow border) and the 
outcome informing them they have not lost money (indicated by an empty circle). 
On the next trial the subject grips again however this is a switch trial and therefore 
when the subject grips they do not win money (indicated by a pound sign with a 
cross through it). On the next trial the subject switches their behaviour and now 
does not grip in response to the symbol (indicated by the blue border) and now does 
not lose money. The same process is occurring in parallel with a different symbol 
which switches from a no-grip to avoid loss to a grip to avoid loss at the same time. 
Also not depicted are the null outcome trials in which subjects can either continue to 
receive one pound (indicated by a pound coin) or receive a null outcome (indicated 
by an empty circle). 
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MRI scanning 
The study was conducted at the Wellcome Trust Center for Neuroimaging, at UCL 
using a 3T Siemens Allegra scanner equipped with a Siemens head coil. Anatomical 
images were acquired using magnetization-prepared rapid-acquisition gradient 
echo scans, which were followed by 1-mm-thick axial slices parallel to the anterior 
commissure–posterior commissure plane.  Functional scans used a gradient echo 
sequence; repetition time, 2.86s; echo time 25 ms; flip angle 90 degree; matrix size 
128x72; field of view 192 mm; slice thickness, 2 mm and interslice distance factor of 
1mm.  A total of 44 axial slices were sampled. The in-plane resolution was 3 x 3 mm. 
Functional imaging data were analyzed using statistical parametric mapping 
software (SPM8; Wellcome Trust Centre for Neuroimaging, London, UK; 
http://www.fil.ion.ucl.ac.uk/spm). Images were realigned with the first volume 
(after discarding the first six dummy volumes) and unwarped, normalized to a 
standard echo-planar imaging template based on the Montreal Neurological 
Institute reference brain, resampled to 3 x 3 x 3mm voxels, and spatially smoothed 
(8 mm full width at half-maximum). 
6.2.4 Data analysis 
Behaviour 
The critical behavioural trial occurred on a switch.  Here, subjects received 
surprising feedback, either a hedonically salient loss or neutral null outcome. This 
instigated a rapid alteration of behaviour following this violation of expectations. 
There were 4 types of trial –Go to avoid loss, NoGo to avoid loss, Go to avoid null, 
NoGo to avoid null and  2 drug states – placebo and L-dopa with a  fully crossed 
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design. Accuracy (proportion correct responses) was computed for each. 
Comparisons between trial-types at the group level were performed by entering 
trial specific results into a three-way (drug x action x valence) repeated measures 
ANOVA. 
 
Trials were separated into ‘Go’ and ‘NoGo’ trials for each of the valence outcomes 
(null /avoid loss) and the accuracy for the different drug sessions were computed 
separately. We also examined reaction times and gripper vigour differences. We 
checked late error Go versus NoGo trials in the separate groups, and performed a 
repeated measures ANOVA looking for interactions between the manipulated 
factors; null/avoid loss, Go/NoGo, L-dopa/placebo. 
 
fMRI analysis: whole-brain general linear model parametric analysis. 
Analysis of functional MRI (fMRI) data proceeded by a hierarchical analysis. At the 
within-subject level, a general linear model (GLM) was constructed containing 
regressors indicating each relevant trial type. There were 8 variables: Onset Go trial 
before switch, T(Go)switch-1; Onset NoGo trial before switch, T(NoGo)switch-1; Onset Go 
switch trial, T(Go)switch; Onset NoGo switch trial, T(NoGo)switch; Onset Go trial after 
switch, T(Go)switch+1; Onset NoGo trial after switch, T(NoGo)switch+1;  Onset remaining 
Go trials; Onset remaining NoGo trials. The second model also contained 8 
regressors:  Onset correct trial before switch, T(corr)switch-1; Onset incorrect trial 
before switch, T(incorr)switch-1; Onset correct switch trial, T(corr)switch; Onset 
incorrect switch trial, T(incorr)switch; Onset correct trial after switch, T(corr)switch+1; 
Onset incorrect trial after switch T(incorr)switch+1;  Onset remaining correct trials; 
Onset remaining incorrect trials. Trial-specific activations were modelled as box-car 
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functions, with durations set according to entire trial length on an individual subject 
basis, convolved with the canonical hemodynamic response function.  Data from 
one subject had to be excluded from the second model due to a very high overall 
accuracy (>95%) thereby preventing out ability to contrast the correct with the 
incorrect trials.  
               
Low frequency drifts were excluded with a high-pass filter (128-s cutoff). Short-term 
temporal autocorrelations were modelled using an AR(1) process. Motion 
correction regressors estimated from the realignment procedure were entered as 
covariates of no interest. Statistical significance was assessed using linear contrasts 
of the regression coefficients from the GLM, generating statistical parametric maps 
(SPM) of t values across the brain for each subject and contrast of interest. Placebo 
and dopamine sessions were separately analysed, and corresponding contrast 
images were taken to the second level as per a hierarchical random-effects analysis, 
entering contrasts for each subject in placebo and levodopa sessions into a group 
level GLM. Paried t-tests were used to make within subject comparisons of drug 
effects. 
Anatomical localization was carried out by overlaying the t-maps on a normalized 
structural image averaged across subjects, and with reference to an anatomical 
atlas (Naidich 2009).  All coordinates are reported in MNI space (Mazziotta et al 
1995).   
  
Region of interest analysis  
Our primary regions of interest were the principal projection fields of midbrain 
dopaminergic afferents, specifically ventral and dorsal striatum and prefrontal 
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cortex (Haber 2003). After identifying significant voxels on a whole brain analysis, 
effect size data (beta values) were extracted from a 4mm sphere centred on peak 
activated voxel.    
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6.3 Results 
Behaviour 
To measure the efficacy of set switching, we calculated response accuracy (i.e. the 
proportion of correct responses) on trials subsequent to a switch of contingencies. 
Initially we characterised normal adaptive behaviour on placebo, where we found 
subjects were better at switching after a surprising/unexpected loss compared with 
an suprising/unexpected null event (paired t-test, null vs loss; T=-3.21 , p=0.006). 
This was entirely consistent with our prediction that loss would be a more potent 
catalyst for behavioural adaptation than null events.    
We also found a switch type (loss/null) by drug (L-dopa/placebo) interaction 
(p=0.004,  F(1,15)=11.73) in the performance accuracy in the trial after the switch 
trial. As hypothesised, L-dopa obliterated the observed difference in performance 
following trials signalled by a hedonically salient surprising loss versus a surprising 
null event, such that accuracy on levodopa was now equivalent for both conditions  
(L-dopa: avoid vs  null, paired t-test; T= 1.0, p=0.332), (figure VI.II).  
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Figure VI.II: Represented is the percent accuracy in the trial after set switch for the 
two different switch types separately (loss – blue bars/null-red bars) and for the two 
drug conditions (placebo and L-dopa). Error bars are within subject error bars. 
Critically, there was no main effect on accuracy of drug (L-dopa/placebo) (F(1,15) = 
0.125, p=0.728) or of switch type (loss/null) (F(1,15)=1.73, p=0.208) or action 
(Go/NoGo) (F=0.249, p=0.625). Thus accuracy was balanced, equivalent across each 
of these factors, such that we could specifically attribute behavioural changes 
following levodopa administration to a loss of the normal switching performance 
differential following hedonically surprising events.  There was no interaction 
between switch type (loss/null) and action (Go/NoGo) (F(1,15)=2.149, p=0.163), or 
drug (L-dopa/placebo) and action (Go/NoGo)  (F(1,15)=0.02, p=0.888).  
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fMRI 
We initially measured baseline neural responses to a violation of expectations, 
given our central neural hypothesis that such responses drive subsequent 
behavioural set shifts. Thus, we computed the contrast [Tswitch-1 – Tswitch], which 
localises differences in neural responses for trials with fully expected outcomes 
Tswitch-1 compared with neural responses for surprising switch trials Tswitch (where the 
outcome was unexpectedly incorrect) (figure VI.IIIA). This contrast between 
expected and unexpected responses was expressed in the vmPFC and NAc.  
 
As with the behavioural data, we also found an interaction in the parameter 
estimates from the vmPFC (central coordinates x=9, y=26, z=-8) and a significant 
interaction between switch type (avoid/null) and drug state (placebo/L-dopa) 
(F(1,15)=5.05, p=0.04) (figure VI.IIIB). Of note we also found a similar pattern of 
activation in the NAc (central coordinates x=-3, y=11, z=-2), whereby successful set 
shifting in the placebo avoid loss trials was associated with decreases in NAc activity 
with the reverse pattern in the L-dopa group.  This effect only reached trend 
significance in the placebo group (one sample t-test placebo avoid T=-1.89, p= 
0.077; one sample t-test L-dopa null T=-2.19,p= 0.044;) and there was no 
interaction.  
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Figure VI.III : Neurophysiological responses to violations in expectations.  (A) 
Contrasted is the BOLD activation pattern in the trial before the switch (fully 
expected) minus the switch trial (unexpected) over all conditions (placebo/L-dopa 
and avoid/null). From the comparison of these two trial types activations are seen in 
the vmPFC and NAc. (B) Contrast estimates for the switch trial minus the trial before 
the switch, contingent upon subsequent successful set shifting (i.e. a behaviourally 
validated response). These show the difference in neural response between trials 
with an expected versus an unexpected outcome when a successful set shift occurs 
on the subsequent trial (for the different trial types (loss trials-blue bars, null trials-
red bars). PFC neuronal activity is decreased during unexpected loss in the placebo 
group. In the L-dopa group this decrease is absent on the loss trials and is 
paradoxically only present in the null trials. Represented are the mean parameter 
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estimates (beta values). Error bars are within subject error bars. (C) Contrasted is 
the interaction in the placebo group between successful and unsuccessful set shifts 
in the different trial types for avoid loss compared with null blocks (the contrast is 
successful shifts (avoid minus null) minus unsuccessful shifts (avoid minus null). (D) 
Beta plots representing the interaction in panel C. Illustrated is a decrease in activity 
in vmPFC in the behaviourally validated (successful) set shifts in the placebo group 
compared to the unsuccessful shifts, illustrating the link between the decrease in 
vmPFC activity on switch trials which result in successful behavioural shifting. 
Plotted are the within subject differences in the two drug conditions (placebo –
green bar, L-dopa-purple bar) highlighting a decrease in activation in the placebo 
group when presented with an unexpected loss, an effect absent in the dopamine 
group.  Plotted are the mean parameter estimates (beta values) and error bars 
represent standard error of the mean. The beta plots for the successful and 
unsuccessful trials only includes data from 15 subjects (see methods for details).   
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Basal ganglia loops are topographically distinct, however there is significant 
integration and overlap between the various loops and pathways (Haber 2003). 
Moreover, suppression of responses at one level of a neural hierarchy are often 
coupled to enhanced responses at complementary levels because of reciprocal 
information passing. Given this integration we anticipated that we would find 
reciprocity of response patterns between the mesocortical pathway with its 
projections to the vmPFC, and the nigrostriatal pathway with its projections to the 
caudate and putamen (Haber 2003). 
The reverse contrast [Tswitch – Tswich-1] (fully unexpected minus expected trial) 
highlighted increased activation in the caudate, insula and thalamus for trials with 
unexpected outcomes (figure VI.IV.A). Within these regions we asked whether L-
dopa also modulated this pattern of enhanced activation.  We indeed found that 
dopamine modulated caudate activity (central coordinates x=-12, y=5, z=7) in the 
unexpected minus expected trials (figure VI.IV.B). Contrast estimates demonstrate a 
clear reciprocity between the vmPFC and caudate activations (figure VI.IV.C). 
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Figure  VI.IV : Neurophysiological responses to violations in expectations.  
 (A) Contrasted is BOLD activation pattern in the switch trial (unexpected) minus the 
trial before the switch (fully expected) over all conditions (placebo/L-dopa and 
avoid/null). From the comparison of these two trial types activation in the insula, 
thalamus and caudate emerge. (B)  Contrasted is the BOLD activation pattern in the 
switch trial (unexpected) minus the trial before the switch (fully expected) in the L-
dopa minus placebo data.  (C) Beta plots for switch trial minus the previous trial 
(before the switch) in the caudate and the vmPFC. The beta plots represent the 
difference between an unexpected and expected outcome when a successful set 
shift occurs on the subsequent trial (behaviourally validated set switch) for the 
different trial types. This illustrates an apparent dip in neuronal activity in the 
placebo group associated with an unexpected loss in the vmPFC. In the L-dopa group 
this effect is absent on loss trials and paradoxically is only present in the null trials. 
Conversely, the activity in the caudate shows an opposite pattern to that observed 
in the vmPFC. Represented are the mean parameter estimates (beta values) and 
error bars are within subject error bars. The beta plots for successful and 
unsuccessful trials only includes data from 15 subjects (see methods for details). 
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6.4 Discussion 
Here, I aimed to characterise the influence of dopamine on the neurobiological 
processes that support set switching. I employed a stringent balanced design to 
control for purported possible effects of dopamine on movement and motor vigour 
(requiring both action and the omission of action as a response), and to disentangle 
effects of dopamine on non-specific violations of sensory predictions from salient, 
negatively hedonic surprise.   
 
The appropriate shifts of behaviour in the face of aversive outcomes is a central 
evolutionary skill and the inability to correctly learn from punishments is a feature 
of many pathological lesions and conditions (Bechara 2005; Patterson & Newman 
1993) . I aimed to elucidate the precise role of dopamine in this adaptive ability and 
as such to provide an explanation for impairments observed in disorders in which 
abnormal dopaminergic transmission is implicated (Berke & Hyman 2000; Evans et 
al 2009).  
 
In the normal (placebo) state, subjects are highly skilled at rapidly altering 
behaviour following unexpected negative violations of expectations, but conversely 
are significantly less successful at set switching when the violation of expectations 
is signalled by a null outcome. Adaptive survival mechanisms, conferred by 
evolutionary selective pressures, are necessarily tuned to the avoidance of 
significant loss. It is therefore unsurprising to find such a striking asymmetry in 
behaviour determined by the hedonic valence of outcomes. Moreover, one would 
174 
 
expect the dopaminergic system to be optimised for such behaviour in healthy 
individuals. 
 
This normal pattern of behaviour is in stark contrast to that observed when 
dopaminergic transmission is perturbed by the administration of L-dopa. On L-dopa, 
the ability of subjects to shift behaviour in response to negative violations of 
expectations was obliterated, with a significant decrement in the performance of 
subjects in this condition. Furthermore, when subjects were given L-dopa, we 
observed a reversal of the normal pattern of behaviour whereby subjects were 
better at set switching in response to null outcomes, albeit non significantly but 
leading to a two way drug by valence interaction. Simultaneously collected imaging 
data revealed a potential mechanism of this observed behaviour. 
 
Dopamine plays a central role in the maintenance of working memory (Fuster 2001; 
Sawaguchi & Goldman-Rakic 1991; Stuss & Knight 2002b) and the representations 
of behavioural sets by delay period activity in the prefrontal cortex (Funahashi et al 
1989; Fuster & Alexander 1971). Neurons in this region do not only code for stimuli 
and actions but also convey behavioural context (Asaad et al 2000). A current 
behavioural set is hypothesised to be encoded by a specific pattern of itinerant 
dynamics representing an entrained sequence of predicted states (Friston 1997; 
Rabinovich et al 2008). This entrainment is supported by dopamine, hence a strong 
prediction is that withdrawal of dopaminergic modulation in response to violations 
of expectations is required to allow the release from one pattern of attractor 
dynamics and the subsequent establishment of an alternate pattern thus facilitating 
a set switch. As predicted, we observed this pattern both in the vmPFC and NAc, 
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key projection structures of the dopaminergic pathways (Arias-Carrion & Poppel 
2007; Haber 2003). 
 
Significantly, this effect was marked only for hedonically surprising outcomes with 
negative valence, supporting the behavioural observation of enhanced 
performance after adaptively relevant losses. Moreover, disrupting brain dopamine 
levels by pre-treating with L-dopa not only attenuated the difference between 
negatively valenced and null events, but in fact reversed this pattern of neural 
activation.    
 
The PFC also has been suggested to represent action (Fuster 2001), and dopamine 
has been shown to influence motor responses (Salamone et al 2003), it was 
therefore essential to control for motor execution when attempting to dissociate 
the role of dopamine in set shifting. Importantly, our observed effects, both 
subcortically and in vmPFC, were invariant to the execution or omission of a motor 
response. This strongly supports the notion that this network encodes a 
behavioural set per se, independent of the commission of action, and that 
dopamine enables the maintenance of a representation of specific state-sequences, 
rather than simply facilitating movement. 
 
It is entirely understandable that perturbation of the dopaminergic system, with its 
widespread projections to the PFC and NAc (Arias-Carrion & Poppel 2007; Haber 
2003), will worsen task performance in healthy individuals as intrinsic dopamine 
levels in healthy individuals are likely to be optimised. Indeed, it has been shown 
that the relationship between dopamine and performance in many cognitive tasks, 
176 
 
especially those relying on working memory (Stuss & Knight 2002a), follows an 
inverted U-shaped function with both reducing or increasing the levels of dopamine 
leading to worsened task performance (Cools 2006; Cools & D'Esposito 2011; 
Robbins 2000; Williams & Goldman-Rakic 1995). In PD patients it has been 
demonstrated that while L-dopa administration might improve motor function it 
can move them away from their cognitive optimum (Gotham et al 1988; Rowe et al 
2008), putatively by an ‘overdosing’ of the cortico-striatal loop involved in the task 
in question. Concordant with our findings, although within the confines of a very 
different task, L-dopa administration to Parkinson’s patients impaired performance 
in probabilistic reversal learning and mainly in those which are signalled by negative 
feedback (Cools et al 2006; Cools et al 2001a). Furthermore, PD patients have been 
shown to have deficits in other tasks which require behavioural adaptation after 
rule changes (Cools et al 2001b; Gotham et al 1988). These behavioural deficits 
have been associated with abnormal activations in the cortex and striatum in PD 
patients, which were further dependant on whether positive or negative feedback 
were received (Monchi et al 2004), pointing to an influence of both dopaminergic 
status and feedback type on tasks of this ilk.    
We additionally predicted a reciprocity in activation patterns between subcortical 
and cortical structures receiving major dopaminergic projections.  We indeed 
observed such reciprocity with decreases in prefrontal activity concurrent with 
increases in caudate activity. This finding is in keeping with the known 
neurochemical reciprocity between the PFC and striatum whereby increases in 
dopamine in the PFC are associated with decreased dopamine in the basal ganglia 
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and vice versa (Pycock et al 1980; van Schouwenburg et al 2010), and also with the 
involvement of the caudate in tasks of this type (Clarke et al 2011). It may also be 
reflective of the different time courses of activity in the PFC and striatum which has 
been demonstrated in several tasks (Fujii & Graybiel 2005; Pasupathy & Miller 
2005), and accords with theories suggesting a ‘gating’ role for the basal ganglia 
(Frank & Claus 2006; McNab & Klingberg 2008), and specifically a critical role for 
dopamine in this ‘gating’ (Miller & Cohen 2001).  
It has been suggested that dopamine in the PFC and the basal ganglia regulate the 
balance between 2 functionally opponent processes, with the PFC dopamine 
regulating stability and the basal ganglia dopamine promoting cognitive flexibility 
(Cools 2008; van Schouwenburg et al 2010). Our data enriches these theories by 
suggesting that meta-stable representations of behavioural set are maintained in 
PFC under dopaminergic influence, and that the destruction and reestablishment of 
these cortical dynamics corresponding to a set switch, relies on a transient 
suppression of dopaminergically mediated activity following a hedonically 
surprising, negatively valenced outcome; a suppression of activity which we disrupt 
by exogenous L-dopa administration. 
 
My central finding that dopamine administration abolishes the innate ability of 
healthy humans to alter behaviour in the face of negative outcomes, has great 
clinical relevance for understanding impulse control disorders observed in 
Parkinson’s disease patients. These patients suffer from compulsive and impulsive 
behaviours as a result of dopamine replacement medication whereby they are 
unable to disengage with seemingly pointless activities such as compulsive 
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gardening and grooming even when these lead to negative life outcomes (Evans et 
al 2004; Evans et al 2009; McKeon et al 2007). A blunting or reversal of the normal 
suppression of activity could provide an explanation for this paradoxical 
maintenance of behavioural set in the face of negative outcomes. Here we propose 
possible neurobiological mechanisms for these behavioural disorders, and 
demonstrate a pervasive neurobiological role of dopamine in both stability and 
switching of responses which transcends action.  
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Chapter 7  
Discussion  
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7.1 Summary of main results 
Dopamine is a central neurotransmitter in the basal ganglia and influences many 
different aspects of behaviour. Among its many roles, dopamine has effects on both 
learning (Bayer & Glimcher 2005; Schultz 1998; Schultz et al 1997; Wise 2004; Wise 
& Rompre 1989) and on performance (i.e. on the expression of learnt behaviour) 
(Bardgett et al 2009; Berridge 2007; Boureau & Dayan 2011; Dickinson et al 2000; 
Mazzoni et al 2007; Niv 2007; Parkinson et al 2002; Salamone et al 2003).  As 
described earlier in this thesis, these effects are confounded in many experiments 
involving dopamine manipulations (Cools et al 2007b; Frank et al 2007; Frank et al 
2004; Pessiglione et al 2006).  
In my first experiment, Dopamine and performance in a reinforcement learning task 
– evidence from Parkinson’s disease (see Chapters 3 and 4), I was able to distinguish 
these factors by utilising the model afforded by Parkinson's Disease (PD) and 
performing a within-subject controlled drug manipulation.  This allowed me to test 
whether the previously observed impairments in reinforcement learning in PD 
(Frank et al 2004; Knowlton et al 1996) were attributable to the effect of dopamine 
depletion on the learning process itself or on the expression of learning, i.e. on 
action performance.  
By testing patients in different drug states I found that the main effect of dopamine 
was actually on the performance rather than the learning aspect of feedback-
related learning, a finding which poses a challenge to many theories on the role of 
dopamine in learning (Bayer & Glimcher 2005; Frank et al 2007; Frank et al 2004; 
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O'Doherty et al 2003; Pessiglione et al 2006; Schultz et al 1997). At the neural level, 
the improved accuracy observed during the performance stage in the patients who 
were ON medication (irrelevant of which state they had been in when they learnt 
the contingencies) was associated with enhanced nucleus accumbens (NAc) and 
ventromedial prefrontal cortex (vmPFC) activity for the chosen cue value, an effect 
absent in the OFF medication state. The enhanced activity in the NAc and vmPFC in 
the ON medication state (which correlated with the improved behaviour) suggests 
that enhanced cue value representation underlies successful choice behaviour by 
improving patients’ ability to choose the better outcome in novel contexts either by 
a more stable cue value representation or by improving the ability to compare the 
values of stimuli leading to such outcomes.  
 
These findings are important for the clinical and neuroscientific community as they 
potentially clarify effects of dopamine and also allow an improved understanding of 
how the various roles of dopamine interact and overlap. This overlap has previously 
made it difficult to differentiate between dopamine’s various roles, and I was able 
to achieve this differention by using the human model of dopamine depletion 
provided by PD.  
My second experiment, The effect of valence on movement: a study of bradykinesia 
in Parkinson’s disease (see Chapter 5) utilised the findings of the first experiment 
and went on to demonstrate a link between the cognitive and motor deficits 
observed in Parkinson’s disease.  A key result from my first experiment was that 
patients OFF medication are impaired at subsequently picking the most rewarding 
stimuli (thereby leading to lower accuracy in the task overall). In this first 
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experiment however, there were no specifically aversive outcomes (only outcomes 
which were more or less likely to be probabilistically correct). Consequently, I then 
questioned as to what effect dopamine depletion would have on specifically 
aversive outcomes and furthermore whether this would have an effect on 
bradykinesia, one of the main movement deficits found in PD.  
 
In designing the second experiment, my aim was to establish whether the reward 
insensitivity in this group (i.e. PD patients OFF medication) would carry over into 
the motor domain by comparing the performance of PD subjects in rewarding 
scenarios to aversive ones. The impaired responsiveness to rewards which we 
observed in the first experiment when dopamine levels were low (due to disease), 
was not surprising given the pivotal role dopamine plays in reward (Bayer & 
Glimcher 2005; Day et al 2006; Schultz et al 1997).  Indeed, the impaired 
adjustment of movement time in response to rewards has previously been shown 
in PD patients OFF medication (Moustafa et al 2008).  What I aimed to demonstrate 
however, was that this deficit would be manifest in impaired motor speed to 
rewarding stimuli but less so to aversive stimuli. 
  
The results confirmed our predictions in that I was able to clearly demonstrate a 
valence asymmetry in the movement time of PD patients, whereby there is a 
comparative failure to speed up in order to win rewards compared with an ability to 
speed up in order to avoid punishments. We also found that although the trial-by-
trial response to rewards was impaired in the PD group, the trial-by-trial response 
to punishments was not similarly impacted, a finding which has not previously been 
demonstrated.  Finally, we also found a detrimental effect of distractors which was 
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only evident for shock trials in PD patients, showing that sensitivity to distraction is 
also valence specific. These findings are important, as they demonstrate that 
movement time in PD is dependent on valence context, in other words whether 
movements are to harness a reward or avoid a punishment matters. I found that 
there is an asymmetry in patients’ ability to move fast in response to rewards 
compared to punishments, demonstrating that even when tested in the context of 
everyday outcomes, bradykinesia is a variable, context-dependent deficit. 
 
The above findings support the hypothesis that there is significant overlap between 
the motor and associative/limbic basal ganglia loops and provide empirical 
evidence that one can significantly impact on the other. It also supports hypotheses 
that the striatum and dopaminergic transmission are key to this influence (Haber 
2003; Mogenson et al 1980). The results of my second experiment also have direct 
clinical relevance for PD patients. By showing that attention and implicit motivation 
are significant contributors to movement time in this group of patients, physical 
therapies in the future might be usefully adapted to take account of this fact 
leading to increased effectiveness and better outcomes.   
 
In my third experiment, Expectations and violations: Probing the role of dopamine 
in set shifting  (see Chapter 6), I  turned my attention away from the effects of 
dopamine depletion and studied how boosting dopamine affects behaviour in the 
context of set shifting. For this experiment, using healthy human subjects, I isolated 
the effect of dopamine on set switching by specifically controlling for both its 
effects on motor vigour and for its effect on responses to violations of sensory 
predictions. I found that only subjects with normal dopaminergic function (i.e. 
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which have not been perturbed by administration of L-dopa), could effectively set 
switch in response to cues which carry negative valence. When these same subjects 
were given dopamine they lost this native ability, demonstrating that “overdosing” 
the dopaminergic system leads to deficits in responses to negative violations of 
expectations. Furthermore, when subjects were under the influence of L-dopa we 
observed a reversal of the normal pattern of behaviour whereby subjects became 
slightly (albeit not significantly) better at set switching in response to null outcomes 
compared to outcomes with negative valence, leading to a two way drug by valence 
interaction.  
Effective set switching in the placebo group was associated with a larger decrease 
in PFC neuronal activity during unexpected losses (when the unexpected switch trial 
was contrasted with the fully expected pre-shift trial). In the L-dopa group this 
decrease in neuronal activity was absent on loss trials and paradoxically was only 
present in the null trials. These results support hypotheses that the relationship 
between dopamine and performance in many cognitive tasks, especially those 
relying on working memory (Stuss & Knight 2002), follow an inverted U-shaped 
function whereby the optimum level of performance exists at a certain level of 
dopaminergic stimulation. Any movement away from that peak (either by artificially 
reducing or increasing the levels of dopamine) leads to worsened task performance 
(Cools 2006; Cools & D'Esposito 2011; Gotham et al 1988; Robbins 2000; Rowe et al 
2008; Williams & Goldman-Rakic 1995). 
It is reasonable to assume that humans have evolved to have the optimal 
dopaminergic system for survival, with a fine balance being achieved between the 
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evolutionary need to avoid aversive cues, which could signal death or injury (with 
disastrous results which should therefore be avoided at even high costs), while 
maintaining appropriate responses to neutral or rewarding stimuli. In fact, the 
inability to learn correctly from punishments is a feature of many pathological 
lesions and conditions (Bechara 2005; Patterson & Newman 1993). The results of 
my research indicate that this fine balance can be altered by modulation of the 
dopaminergic system.  It further demonstrates that: (a) low levels of dopamine such 
as are found in unmedicated PD patients is associated with poor responses, both in 
motor and cognitive tasks, to rewarding stimuli but a relatively preserved responses 
to aversive outcomes; (b) augmented dopamine states, such as when PD patients 
are given dopamine replacement therapy (DRT) or when healthy subjects are given 
L-dopa, are associated with improved performance in relation to null or positive 
outcomes but can lead to less effective responses to loss outcomes; and (c) in 
healthy controls who have normal, unperturbed dopaminergic systems, there is a 
bias towards better responding to negative outcomes. Evidence for this comes from 
the second experiment (Chapter 5) in which the movement times in the control 
group were faster when subjects avoided aversive outcomes compared to when 
they tried  to reap rewarding outcomes which  demonstrates that the avoidance 
(moving away from) pain is of greater importance than a successful pursuit of 
reward. Further evidence for this evolutionary asymmetry comes from the placebo 
group in the third experiment (Chapter 6) whereby this group showed more 
effective set shifting in response to losses compared with null outcomes, when all 
other major factors were controlled for.  It appears therefore that low dopamine 
states exacerbate this evolutionarily proscribed asymmetry, where there is a bias 
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towards better loss avoidance, an asymmetry eliminated under artificially raised 
dopamine states. 
Note that all of the effects I have found are separate from those on learning. In the 
first experiment, when we attempted to separate learning from performance, we 
found that dopamine exerted its effects primarily on the expression of learning 
rather than on learning itself. In the second experiment no significant learning took 
place. In the third experiment we examined set shifting as opposed to directly 
testing learning.   
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7.2 Implications for theories of dopamine function 
As mentioned above, dopamine has been implicated in many different aspects of 
cogntion including learning (Montague et al 2004; Schultz et al 1997), motivation 
and vigour (Salamone & Correa 2002; Ungerstedt 1971) and action selection and 
movement (O'Doherty 2004; Samejima et al 2005). In the experiments in this thesis 
I sought to disambiguate several of these functions from one another in order to 
attempt to improve the understanding of the function of dopamine. The results of 
the first experiment indicate a central role for dopamine in the performance aspect 
of reinforcement learning rather then on learning. Our results indicate that levels of 
dopamine do not impact on actual learning but rather on the expression of that 
learning in contrary to many previous accounts (Bayer & Glimcher 2005; Frank et al 
2007; Frank et al 2004). One of the reasons for the differences between our results 
and previous findings may be in part due to many previous experiments 
confounding learning and performance. There are however many different types of 
learning which lead to various behavioural outputs (Dickinson et al 2000; Palmiter 
2008) and as such the lack of an effect of dopamine on learning in our specific 
experiment does not of course rule out a role for dopamine entirely in learning. I do 
believe however that this experiment should act as an example for future work of 
the importance of using tasks optimised for isolating specific functions to avoid the 
possibility of confounding the various roles of dopamine.  In relation to the seminal 
work of Schultz (Schultz et al 1997) and the reward prediction error findings in 
animals, our data cannot specifically address the issue of whether prediction error 
related activity is the main driving force behind learning or instead occurs as a 
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consequence of learning as proposed by Berridge and Robinson (Berridge 2007; 
Berridge & Robinson 1998) only that we could not isolate a direct effect of 
manipulating dopamine on learning.  
Dopamine has been widely implicated directly in reward processing (Wise 1978) in 
both animals and in humans. This is an extra complicating factor when attempting 
to disambiguate the roles of dopamine from each other. As a consequence of this 
fact, the second experiment sought to detect whether the effect of valence would 
carry influence motor output directly, while the third experiment directly examined 
the role of valence in the ability of humans to set shift  in both normal and boosted 
dopamine states. We found that valence is in fact a critical factor in the function of 
dopamine and even when other factors are controlled for it exerts one of its main 
effect in this domain. This in turn has both implications for PD (see next section) 
and for understanding human motivated behaviour in general.   
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7.3 Implications for PD 
The research I have carried out and have detailed in this thesis makes a potentially 
important contribution to our understanding of the origins of some of the deficits 
observed in Parkinson’s disease. The results of the first experiment demonstrate 
that low dopamine levels detrimentally impact value representation in decision 
making in novel contexts, an ability restored by dopamine treatment.  The key 
clinical implication of this finding is that patients’ decision making abilities are 
affected by dopamine replacement therapy.  
Most patients and physicians are unaware that administration of DRT can have an 
effect on even the simplest of implicit choices and that this effect could have 
detrimental consequences on both the major and minor everyday decisions which 
patients make. In addition, the improvement in reward related performance 
observed in patients who are on their DRT provides a potential explanation of some 
of the compulsive behaviours observed in patients who overuse dopamine 
medication. From this work, we can infer that even in PD patients who do not suffer 
with overt impulse control disorders, dopaminergic medication is having an effect 
on the choices they make and on their ability to respond correctly to stimuli with 
different valence characteristics. This has important implications to PD and its 
treatment and has relevance to the day-to-day choices patients make.   Patients 
and the physicians who treat them need to be more aware of this effect of 
medication on cognition.  
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In the second experiment, I link the different responses to positive and negative 
outcomes to the movement deficit observed in PD patients and in doing so 
demonstrate that the outcome of a movement (i.e. reap a positive outcome or 
avoid a negative outcome) impacts the speed of movement and that this 
asymmetry is more marked in PD patients than in controls. This demonstrates that 
dopamine depletion has a lesser impact on responses to punishments compared to 
rewards. This finding provides a potential explanation for the paradoxical kinesis 
observed in PD patients, whereby patients are suddenly able to move at near 
normal speeds, usually in extreme aversive contexts, and also demonstrated that 
everyday outcomes can have very different effects on movement time in PD. The 
understanding that Parkinson’s disease patients’ ability to move might  depend on 
factors that may have previously not been considered as relevant could lead to 
more effective future strategies in physical therapy.  
Finally, in the third experiment, I have shown that overdosing the dopaminergic 
system in healthy individuals leads to a performance decrement in set shifting as 
well as a loss of the innate ability to avoid aversive outcomes. Overdosing the 
dopaminergic system actually leads to subjects responding abnormally to null 
outcomes. This is in keeping with theories on the inverted U-shaped function 
whereby the optimum level of performance exists at a certain level of dopaminergic 
stimulation, and any movement away from that peak (either by artificially reducing 
or increasing the levels of dopamine) leads to worsened task performance. This has 
been clearly demonstrated in several studies on PD patients (Cools et al 2001a; 
Cools & D'Esposito 2011) and has been proposed to be due to the overdosing of the 
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ventral striatal orbitofrontal circuity which is relatively unaffected in early PD (Cools 
et al 2001a).  Here we propose a central role for valence in behaviour, and that a 
similar U-shaped function may exist in this domain as well and that depletion of 
dopamine (such as is found in the PD state) enhances the effect of negative 
outcomes on behaviour and boosting dopamine, either in healthy or parkinsonian 
patients enhances the effect of cues which yield positive outcomes.    
A blunting or reversal of the normal response to outcomes which carry negative 
valence could provide an explanation for the paradoxical maintenance of 
behavioural sets in the face of negative outcomes observed in PD patients who 
compulsively use dopaminergic medication (Evans et al 2004) and potentially in 
addictive disorders in general (Bechara 2005; Patterson & Newman 1993). Impulse 
control disorders in PD are common with prevalence rates of 13.6%. They consist of 
behaviours such as pathological gambling, compulsive buying, compulsive sexual 
behavior, and binge or compulsive eating and have a strong association with the 
use of dopaminergic medication. Dopamine agonist treatment in PD is associated 
with a 2-3.5 fold increase in these behaviours (Voon et al 2011; Weintraub et al 
2010). It is clear that they are important disorders which are influenced by 
dopaminergic medication. Here we propose a possible mechanism for these 
disorders.  
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7.4 Conclusions and future directions 
The aim of my research which I have detailed in this thesis was to probe the effects 
of dopamine on cognition and to attempt, with this knowledge, to understand more 
about the cognitive effects of Parkinson’s disease, a disorder characterised by loss 
of dopamine. To this end I utilised the model afforded by these patients and tested 
them in different medication states with the hope of elucidating the effects of 
dopamine in the various cognitive domains. As detailed previously however, using 
Parkinson’s disease as a model for dopamine depletion is problematic in several 
ways. Firstly other neurotransmitters such as serotonin and acetylcholine are 
affected in PD as well as the fact that PD patients tend to be older, a factor also 
associated with decline in other neurotransmitters. In addition, Parkinson’s disease 
patients are a very hetrogenous group, thereby making inferences about this 
population difficult to apply across the board. Despite all these caveats, Parkinson’s 
disease remains the only viable model of dopamine depletion in humans and I 
therefore believe that much about both the disease and about the function of 
dopamine in the healthy brain can be understood by testing these patients.      
There are several key findings that arise from the research which I have 
undertaken. By disambiguating learning from performance in a key reinforcement 
learning task I have been able to demonstrate that dopamine exerts a critical effect 
on performance which is separate and more important than the effect it has on 
learning. This finding provides a challenge to much of the learning literature and 
provides important insights into the function of dopamine.  
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A further central finding from this work is that dopamine appears to exert an effect 
on responsiveness to cues with different valence contexts, with boosted dopamine 
states increasing responsiveness to positive or null outcomes, while unperturbed or 
depleted dopamine levels associated with better responsiveness to outcomes with 
negative valence. This finding was evident even when the effects of action were 
controlled for.  This has implications in the search for a better understanding of 
compulsive disorders in PD, which are associated with the use of dopaminergic 
medication (Weintraub et al 2010). 
Another key finding from my research is to provide evidence to support the 
hypotheses that activity in one loop of the basal ganglia may be influenced by 
activity in a separate loop (Haber 2003; Haber & Knutson 2010; Redgrave et al 
2010). In the second experiment I demonstrate, by comparing Parkinson’s disease 
patients and controls, that the cognitive loops processing reward and punishment 
exert a distinct impact on motor performance. Furthermore, I show that 
bradykinetic movements in PD are dependent on context, and that in the dopamine 
depleted state, responses to rewards are impaired while responses to punishments 
are relatively well maintained– which is both a novel and important finding. In the 
third experiment, I provide empirical evidence for the reciprocity of response 
patterns between the mesocortical projections to the vmPFC, and the nigrostriatal 
projections to the caudate and putamen. These findings, put together, persuasively 
demonstrate that these loops are both influenced and modulated by one another, 
and support the hypotheses suggesting that limbic inputs influence motor output 
via the striatal loops and are under the influence of the dopaminergic system 
(Haber 2003; Mogenson et al 1980; Roitman et al 2005).   
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In sum, I hope that the findings from this work will significantly contribute to the 
growing knowledge base surrounding the function of dopamine. These findings 
could have important implications: 
(a)  for PD patients by providing a better understanding of the cognitive deficits 
manifest in this disease thereby leading to better management strategies in 
the future, as well as a greater understanding of the implications of the use 
of certain forms of current treatment; 
(b) as a basis for future work exploring and building a better understanding of 
the functions of dopamine in the healthy brain; and 
(c) by pointing to possible neurobiological mechanisms which underlie 
compulsive disorders.  
 
In order to build on this research, in the future I would be interested in focussing on 
the modulatory role of dopamine in different types of learning by by using careful 
experimental designs.  
Given the influence of almost all neurotransmitters on action as well as cognition, 
widespread utilisation of the Go/NoGo task design will allow for better and more 
accurate control of the effects of action, eliminating as much as possible this very 
important confound.   
I would also be interested in examining further the effect of dopamine replacement 
in PD on responses to punishments and rewards by examining motor performance 
in a similar fashion to the experiment in chapter 5. Furthermore , it would be of 
interest to examine the interaction between medication status and graded rewards 
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and punishments in a large sample size of PD patients and matched controls to 
further clarify these effects.  
Another direction I would be keen to pursue is to examine the performance of PD 
patients on my final experiment, in which I have so far only tested healthy 
volunteers on placebo and on L-dopa. This would allow me to examine the 
influence of valence on set shifting in PD while fully controlling for motor output by 
using this Go/NoGo design. In fact, results from an experiment such as this and 
those detailed above would provide important support for some of the conclusions 
of this thesis that have led to the proposal that above many other factors, 
dopamine has a central influence on the modulation of cognitive performance in 
relation to different valence outcomes. 
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